<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74648</article-id><article-id pub-id-type="doi">10.7554/eLife.74648</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-256735"><name><surname>Nichols</surname><given-names>Aaron L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9341-0049</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-258891"><name><surname>Blumenfeld</surname><given-names>Zack</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4627-5582</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-164275"><name><surname>Fan</surname><given-names>Chengcheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4213-5758</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-258892"><name><surname>Luebbert</surname><given-names>Laura</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1379-2927</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258906"><name><surname>Blom</surname><given-names>Annet EM</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258907"><name><surname>Cohen</surname><given-names>Bruce N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-60763"><name><surname>Marvin</surname><given-names>Jonathan S</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258908"><name><surname>Borden</surname><given-names>Philip M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258909"><name><surname>Kim</surname><given-names>Charlene H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-98971"><name><surname>Muthusamy</surname><given-names>Anand K</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258910"><name><surname>Shivange</surname><given-names>Amol V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4169-2969</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258911"><name><surname>Knox</surname><given-names>Hailey J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258913"><name><surname>Campello</surname><given-names>Hugo Rego</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258912"><name><surname>Wang</surname><given-names>Jonathan H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258914"><name><surname>Dougherty</surname><given-names>Dennis A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-258916"><name><surname>Looger</surname><given-names>Loren L</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258915"><name><surname>Gallagher</surname><given-names>Timothy</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-8916"><name><surname>Rees</surname><given-names>Douglas C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4073-1185</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-32482"><name><surname>Lester</surname><given-names>Henry A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5470-5255</contrib-id><email>lester@caltech.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Division of Biology and Biological Engineering, California Institute of Technology</institution><addr-line><named-content content-type="city">Pasadena</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Keck School of Medicine, University of Southern California</institution><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Division of Chemistry and Chemical Engineering, California Institute of Technology</institution><addr-line><named-content content-type="city">Pasadena</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Institute of Biology, Leiden University</institution><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff5"><label>5</label><institution>Janelia Research Campus, Howard Hughes Medical Institute</institution><addr-line><named-content content-type="city">Ashburn</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>School of Chemistry, University of Bristol</institution><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution>Howard Hughes Medical Institute, California Institute of Technology</institution><addr-line><named-content content-type="city">Pasadena</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yellen</surname><given-names>Gary</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Senior Editor</role><aff><institution>National Institute of Neurological Disorders and Stroke, National Institutes of Health</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>04</day><month>01</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74648</elocation-id><history><date date-type="received" iso-8601-date="2021-10-12"><day>12</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-03"><day>03</day><month>01</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-10-04"><day>04</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.10.04.463082"/></event></pub-history><permissions><copyright-statement>© 2022, Nichols et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Nichols et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74648-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74648-figures-v2.pdf"/><abstract><p>Nicotinic partial agonists provide an accepted aid for smoking cessation and thus contribute to decreasing tobacco-related disease. Improved drugs constitute a continued area of study. However, there remains no reductionist method to examine the cellular and subcellular pharmacokinetic properties of these compounds in living cells. Here, we developed new intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) for the nicotinic partial agonists dianicline, cytisine, and two cytisine derivatives – 10-fluorocytisine and 9-bromo-10-ethylcytisine. We report the first atomic-scale structures of liganded periplasmic binding protein-based biosensors, accelerating development of iDrugSnFRs and also explaining the activation mechanism. The nicotinic iDrugSnFRs detect their drug partners in solution, as well as at the plasma membrane (PM) and in the endoplasmic reticulum (ER) of cell lines and mouse hippocampal neurons. At the PM, the speed of solution changes limits the growth and decay rates of the fluorescence response in almost all cases. In contrast, we found that rates of membrane crossing differ among these nicotinic drugs by &gt;30-fold. The new nicotinic iDrugSnFRs provide insight into the real-time pharmacokinetic properties of nicotinic agonists and provide a methodology whereby iDrugSnFRs can inform both pharmaceutical neuroscience and addiction neuroscience.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>pharmacokinetics</kwd><kwd>nicotine</kwd><kwd>biosensors</kwd><kwd>nicotinic agonists</kwd><kwd>iDrugSnFRs</kwd><kwd>inside-out pharmacology</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005188</institution-id><institution>Tobacco-Related Disease Research Program</institution></institution-wrap></funding-source><award-id>Postdoctoral Training Fellowship (27FT-0022)</award-id><principal-award-recipient><name><surname>Nichols</surname><given-names>Aaron L</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005188</institution-id><institution>Tobacco-Related Disease Research Program</institution></institution-wrap></funding-source><award-id>High Impact Pilot Award (27IP-0057)</award-id><principal-award-recipient><name><surname>Lester</surname><given-names>Henry A</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005188</institution-id><institution>Tobacco-Related Disease Research Program</institution></institution-wrap></funding-source><award-id>High Impact Research Project Award (T29IR0455)</award-id><principal-award-recipient><name><surname>Dougherty</surname><given-names>Dennis A</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>Research Project (GM-123582</award-id><principal-award-recipient><name><surname>Lester</surname><given-names>Henry A</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>R21,DA043829</award-id><principal-award-recipient><name><surname>Lester</surname><given-names>Henry A</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Marvin</surname><given-names>Jonathan S</given-names></name><name><surname>Rees</surname><given-names>Douglas C</given-names></name><name><surname>Looger</surname><given-names>Loren L</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>Engineering and Physical Sciences Research Council</institution></institution-wrap></funding-source><award-id>No. EP/N024117/1</award-id><principal-award-recipient><name><surname>Gallagher</surname><given-names>Timothy</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Leiden University International Studies Fund</institution></institution-wrap></funding-source><award-id>(LISF L18020-1-45)</award-id><principal-award-recipient><name><surname>Luebbert</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>Exploratory/Developmental Grants (R21) (DA049140)</award-id><principal-award-recipient><name><surname>Muthusamy</surname><given-names>Anand K</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>Predoctoral Training in Biology and Chemistry (T32) (GM7616)</award-id><principal-award-recipient><name><surname>Muthusamy</surname><given-names>Anand K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Pharmacokinetics, the venerable science that measures the dynamics and concentrations an administered drug attains in organs, has been extended to the subcellular level – organelles – by a generalizable new paradigm.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Smoking cessation is an important goal to help decrease the burden, both individual and societal, of tobacco-related disease. The addictive tobacco alkaloid nicotine itself, via transdermal patches and other devices, remains available for people trying to quit smoking; but nicotine replacement therapy has distressingly low rates of success. Therefore, various research projects are continuing with the aim of developing more effective ligands for nicotinic acetylcholine receptors (nAChRs).</p><p>Prior work suggests that partial agonists with lower efficacy than nicotine could serve as effective smoking-cessation drugs (<xref ref-type="bibr" rid="bib48">Rose et al., 1994</xref>), and efforts continue in that direction (<xref ref-type="bibr" rid="bib47">Rollema and Hurst, 2018</xref>). Another plant alkaloid, (-)-cytisine (also called cytisinicline and Tabex), an α4β2 nAChR partial agonist, served as a basis for the synthesis of analogs that have not yet entered the clinic (<xref ref-type="bibr" rid="bib10">Chellappan et al., 2006</xref>; <xref ref-type="bibr" rid="bib23">Houllier et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">Imming et al., 2001</xref>; <xref ref-type="bibr" rid="bib28">Kozikowski et al., 2007</xref>; <xref ref-type="bibr" rid="bib33">Marcaurelle et al., 2009</xref>; <xref ref-type="bibr" rid="bib41">Philipova et al., 2015</xref>; <xref ref-type="bibr" rid="bib49">Rouden et al., 2002</xref>). Varenicline (Chantix) has four rings, two more than nicotine or cytisine, and is currently the only FDA-approved smoking-cessation drug, but the modest quit rate of ~18% at 12 months invites further investigation (<xref ref-type="bibr" rid="bib11">Coe et al., 2005</xref>; <xref ref-type="bibr" rid="bib36">Mills et al., 2009</xref>). Dianicline, another tetracyclic compound, was discontinued after unfavorable Phase III clinical trials (<xref ref-type="bibr" rid="bib12">Cohen et al., 2003</xref>; <xref ref-type="bibr" rid="bib17">Fagerstrom and Balfour, 2006</xref>).</p><p>A nicotinic ligand for smoking cessation must satisfy at least three criteria (<xref ref-type="bibr" rid="bib46">Rollema et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Tashkin, 2015</xref>). (1) It must enter the brain, where the most nicotine-sensitive nAChRs (α4β2) occur. It must also (2) activate α4β2 nAChRs with an EC<sub>50</sub> sufficient to reduce cravings and withdrawal (1–2 μM). Finally, it must (3) block nicotine binding to reduce the reward phase of smoking (2–30 min). Varenicline meets these criteria, while cytisine (low brain penetration) and dianicline (EC<sub>50</sub> = 18 μM) each fail one of the criteria (<xref ref-type="bibr" rid="bib46">Rollema et al., 2010</xref>).</p><p>Membrane permeation is interesting for investigating and treating nicotine addiction in at least two ways. Firstly, note criterion #1 above. For uncharged molecules, the conventional metric for membrane permeability is logP, where P is the octanol-water partition coefficient. For weak bases including most orally available neural drugs, logP must be corrected to account for the fraction of uncharged (deprotonated) molecules at the pH of interest, usually pH 7.4; the resulting metric, termed logD<sub>pH7.4</sub>, is always less positive than logP. Enhancing the membrane permeability of cytisine analogs and probing nAChR subtype selectivity was addressed via direct functionalization of (-)-cytisine within the pyridone ring (<xref ref-type="bibr" rid="bib45">Rego Campello et al., 2018</xref>). Two of the resulting derivatives, 10-fluorocytisine and 9-bromo-10-ethylcytisine, have cytisine-like EC<sub>50</sub> for the α4β2 nAChRs, but more positive calculated logD<sub>pH7.4</sub> values, suggesting greater membrane permeability at the nearly neutral pH of the blood, brain, and cytoplasm (<xref ref-type="bibr" rid="bib5">Blom et al., 2019</xref>). Estimates of logD<sub>pH7.4</sub> are inexact, extrapolated, or rely on algorithmic calculations whose results differ over 2 log units for individual molecules (<xref ref-type="bibr" rid="bib42">Pieńko et al., 2016</xref>). These estimates have unknown applicability to biological membranes at the logD<sub>pH7.4</sub> values &lt; 0 that characterize varenicline, dianicline, and the cytisine analogs.</p><p>Secondly, nicotine dependence involves one or more ‘inside-out’ mechanisms. Nicotine itself (logD<sub>pH7.4</sub> 0.99) enters the endoplasmic reticulum (ER), binds to nascent nAChRs, becomes a pharmacological chaperone for the nAChRs, and eventually causes selective upregulation of these receptors on the plasma membrane (PM) (<xref ref-type="bibr" rid="bib22">Henderson and Lester, 2015</xref>). For this reason, it is especially important to understand permeation into the ER.</p><p>These two neuroscience aspects of nicotinic ligands – pharmaceutical science and addiction science – call for direct measurements of drug movements in living cells (<xref ref-type="video" rid="video1">Video 1</xref>). We previously explored the subcellular pharmacokinetics of nicotine and varenicline in immortalized cell lines and cultured neurons using the iDrugSnFRs iNicSnFR3a and iNicSnFR3b to visualize that these nicotinic agonists enter the ER within seconds of drug application and exit equally rapidly from the ER upon extracellular washing (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). That nicotine diffuses across cellular membranes in seconds has been suspected for decades: nicotine crosses six PMs to enter the brain within 20 s, providing a ‘buzz.’ That varenicline becomes trapped in acidic vesicles suggests appreciable membrane permeation but may also underlie unwanted effects (<xref ref-type="bibr" rid="bib20">Govind et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Le Houezec, 2003</xref>).</p><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-74648-video1.mp4"><label>Video 1.</label><caption><title>Video morph of PDB 7S7V to 7S7T.</title><p>PBP at the left; cpGFP at the right;key side chains in the linkers are shown as spheres. The ligand, varenicline, is shown as sticks.</p></caption></media><p>We sought to generate and apply additional intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) for candidate smoking-cessation drugs: dianicline, cytisine, 10-fluorocytisine, and 9-bromo-10-ethylcytisine. We hypothesized that a family of newly developed iDrugSnFRs would enable quantifiable fluorescence signals that compare the differences in permeation among these compounds.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Generation of additional nicotinic iDrugSnFRs: Structural tactic</title><p>To generate iDrugSnFRs for cytisine and dianicline, we followed two converging tactics. In the ‘structure-based’ tactic, we obtained the first structural data for OpuBC-based SnFRs bound by nicotinic ligands (nicotine and varenicline) (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Crystals of iNicSnFR3adt in the presence of 10 mM nicotine diffracted to 2.95 Å resolution (PDB 7S7U). Overall, the liganded periplasmic binding protein (PBP) domain of iNicSnFR3adt adopts a closed conformation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In the binding pocket between the top and bottom lobes of the PBP, we observed an ‘avocado’-shaped electron density in the nicotine binding site, enclosed by several aromatic residues (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The combination of protonation/deprotonation and the rotatable bond of nicotine (<xref ref-type="bibr" rid="bib15">Elmore and Dougherty, 2000</xref>) vitiate unambiguously localizing it within the binding pocket.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Apo and ligand-bound structures of iNicSnFR3adt (dt indicates that His<sub>6</sub> and Myc tags have been removed to aid crystallization).</title><p>To form an intensity-based drug-sensing fluorescent reporter (iDrugSnFR), a circularly permuted GFP molecule, flanked by two 4-residue linking sequences, is inserted into a PBP at a position (77–78, in our numbering system) that changes backbone Φ-Ψ angles between the apo and liganded PBP. (<bold>A</bold>) Overall conformation of iNicSnFR3adt crystallized with nicotine; an electron density appears at the nicotine binding site (PDB 7S7U). (<bold>B</bold>) iNicSnFR3adt binding site residues. (<bold>C</bold>) Overall conformation of iNicSnFR3adt with varenicline bound (PDB 7S7T). (<bold>D</bold>) iNicSnFR3adt binding site with varenicline present. (<bold>E</bold>) Aspects of the PBP-Linker1-cpGFP interface, emphasizing contacts that change upon ligand binding. The Phe76-Pro77-Glu78 cluster (in Linker 1) lies 11–16 Å from position 43, which defines the outer rim of the ligand site (<bold>B</bold>); therefore, the cluster makes no direct contact with the ligand site. (<bold>E1</bold>) In the apo conformation, Glu78 acts as a candle snuffer that prevents fluorescence by the chromophore (PDB 7S7V). (<bold>E2</bold>) In the liganded conformation (PDB 7S7T), the Phe76-Pro77-Glu78 cluster moves Glu78 at least 14 Å away from the fluorophore. Pro77 is flanked by Phe76 and Pro396 (in the top lobe of the PBP moiety). The presumably deprotonated Glu78 forms salt bridges with Lys97 and Arg99, both facing outward on the β6 strand of the original GFP (within the original Phe165-Lys-Ile-Arg-His sequence).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Conformational change of apo (PDB 7S7V) to the liganded, closed form (PDB 7S7T) of iNicSnFR3adt.</title><p>The bottom lobe of the PBP is superimposed in the two conformations. With respect to the bottom lobe, the ‘Venus flytrap’ conformational change tilts the top lobe of the PBP but does not change its structure (see Appendix 1). The conformational change also tilts the cpGFP moiety but does not change its structure.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Left: electrostatic surface potential densities for protonated forms of the nicotinic agonists in this study, calculated by SPARTAN at HF/6-31G** theory level.</title><p>The display ranges from –10 to 715 kJ/mol. The molecules are shown on the same distance scale. Right: bond-line skeletal structures for the deprotonated forms.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig1-figsupp2-v2.tif"/></fig></fig-group><p>We obtained an unambiguous ligand placement for iNicSnFR3adt in the presence of 10 mM varenicline in the same crystallization condition. Crystals of iNicSnFR3adt with varenicline bound were isomorphous to those of the nicotine-bound crystals and diffracted to 3.2 Å resolution (PDB 7S7T). While the protein structure (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) is identical to that of the nicotine bound structure (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), the rigidity and additional ring of varenicline allowed us to unambiguously localize it in the binding pocket. Varenicline is enclosed by the same aromatic residues as nicotine, forming cation-π interactions with Tyr65 and Tyr357, in addition to other interactions with the pocket residues (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>The data confirm that similar ligand-induced conformational changes occur in the PBP for nicotine, varenicline, ACh (<xref ref-type="bibr" rid="bib6">Borden et al., 2019</xref>), and choline (<xref ref-type="bibr" rid="bib18">Fan, 2020</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). These changes resemble those for other OpuBC PBPs (<xref ref-type="bibr" rid="bib50">Schiefner et al., 2004</xref>).</p><p>In the full iDrugSnFR, in the apo state, the Glu78 in Linker 1 approaches within ~2.5 Å of the oxygen of the tyrosine fluorophore (<xref ref-type="fig" rid="fig1">Figure 1E1</xref>; PDB 7S7V). <xref ref-type="fig" rid="fig1">Figure 1E2</xref> provides structural details confirming the hypothesis (<xref ref-type="bibr" rid="bib3">Barnett et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Nasu et al., 2021</xref>) that in the liganded state Glu78 has moved away, presumably allowing the fluorescent tyrosinate to form (<xref ref-type="video" rid="video2">Video 2</xref>). We term this mechanism the ‘candle snuffer’.</p><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-74648-video2.mp4"><label>Video 2.</label><caption><title>Video morph of PDB 7S7V to 7S7T.</title><p>PBP at the left; cpGFP at the right; key side chains in the linkers are shown as spheres. The ligand, varenicline, is shown as sticks.</p></caption></media></sec><sec id="s2-2"><title>Generation of additional nicotinic iDrugSnFRs: Mutational tactic</title><p>In the mutational tactic, we screened each drug shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> against a panel of biosensors that included iNicSnFR3a and iNicSnFR3b (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>) and iAChSnFR (<xref ref-type="bibr" rid="bib6">Borden et al., 2019</xref>) as well as intermediate constructs from their development process. From this screen, we chose sensors with the lowest EC<sub>50</sub> for each drug as our starting protein for iDrugSnFR evolution.</p><p>Because the candle snuffer mechanism explains several details of the agonist- and pH sensitivity of both iNicSnFR3a and iSketSnFR (see ‘Discussion’), we presume that it represents a general mechanism for OpuBC-cpGFP SnFRs. We did not mutate residues that lie (in 3D space) between the binding site and linkers.</p><p>For dianicline and cytisine separately, we incrementally applied site-saturation mutagenesis (SSM) to first- and second-shell amino acid positions within the binding pocket. We evaluated each biosensor and drug partner in lysate from <italic>Escherichia coli</italic> and carried forward the biosensor with the highest S-slope to the subsequent round. S-slope, <inline-formula><mml:math id="inf1"><mml:mfrac><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∆</mml:mo><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></inline-formula> at the beginning of the dose–response relation, emphasizes the response to ligand concentrations in the pharmacologically relevant range (<xref ref-type="bibr" rid="bib4">Bera et al., 2019</xref>). <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref> summarize dose–response relations for the optimized sensors. The dianicline sensor, iDianiSnFR, has EC<sub>50</sub> 6.7 ± 0.3 µM, ΔF<sub>max</sub>/F<sub>0</sub> 7.4 ± 0.1, and S-slope 1.1. The cytisine sensor, iCytSnFR, has EC<sub>50</sub> 9.4 ± 0.8 µM, ΔF<sub>max</sub>/F<sub>0</sub> 5.0 ± 0.2, and S-slope 0.5 (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). After generating iCytSnFR, we performed additional SSM to progress from iCytSnFR to SnFRs for 10-fluorocytisine and 9-bromo-10-ethylcytisine. This optimization gave us iCyt_F_SnFR (EC<sub>50</sub> 1.4 ± 0.04 µM, ΔF<sub>max</sub>/F<sub>0</sub> 7.9 ± 0.1, S-slope 5.6) and iCyt_BrEt_SnFR (EC<sub>50</sub> 5.7 ± 0.1 µM, ΔF<sub>max</sub>/F<sub>0</sub> 4.0 ± 0.03, and S-slope 0.7) (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2C and D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Nicotinic agonist intensity-based drug-sensing fluorescent reporter (iDrugSnFR) development.</title><p>Dose–response relations on intermediate constructs using <italic>E. coli</italic> lysate were performed with respective drug partners to identify site-saturation mutagenesis (SSM) winners. (<bold>A–D</bold>) The progenitor biosensor is listed in black. Dashed lines indicate data that did not reach saturation at the concentrations tested; therefore, EC<sub>50</sub> and ∆F<sub>max</sub>/F<sub>0</sub> could not be determined. Development of (<bold>A</bold>) iDianiSnFR, (<bold>B</bold>) iCytSnFR, (<bold>C</bold>) iCyt_F_SnFR, and (<bold>D</bold>) iCyt_BrEt_SnFR.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig2-v2.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Nicotinic agonist intensity-based drug-sensing fluorescent reporter (iDrugSnFR) naming, dose–response relations, and residues mutated.</title><p>Measurements in <italic>E. coli</italic> lysates (L) or with purified protein (P). ND, not determined. Data for iAChSnFR from <xref ref-type="bibr" rid="bib6">Borden et al., 2019</xref>; data for iNicSnFR3b from <xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom"><break/>Informal name</th><th align="left" rowspan="2" valign="bottom"><break/>Drug of interest</th><th align="left" colspan="2" valign="bottom">ΔF<sub>max</sub>/F<sub>0</sub></th><th align="left" colspan="2" valign="bottom">EC<sub>50</sub> (µM)</th><th align="left" colspan="10" valign="bottom">S-slope</th>	</tr><tr><th align="left" valign="bottom">L</th><th align="left" valign="bottom">P</th><th align="left" valign="bottom">L</th><th align="left" valign="bottom">P</th><th align="left" valign="bottom">L</th><th align="left" valign="bottom">P</th><th align="left" valign="bottom">11</th><th align="left" valign="bottom">43</th><th align="left" valign="bottom">44</th><th align="left" valign="bottom">68</th><th align="left" valign="bottom">324</th><th align="left" valign="bottom">360</th><th align="left" valign="bottom">391</th><th align="left" valign="bottom">395</th>	</tr></thead><tbody><tr><td align="left" valign="bottom">iNicSnFR3b</td><td align="left" valign="bottom">Nicotine</td><td align="left" valign="bottom">ND</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">ND</td><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">ND</td><td align="char" char="." valign="bottom">0.5</td><td align="left" valign="bottom">E</td><td align="left" valign="bottom">E</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">H</td><td align="left" valign="bottom">S</td><td align="left" valign="bottom">T</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">G</td>	</tr><tr><td align="left" valign="bottom">iDianiSnFR</td><td align="left" valign="bottom">Dianicline</td><td align="char" char="plusmn" valign="bottom">7.4 ± 0.1</td><td align="char" char="plusmn" valign="bottom">4.7 ± 0.2</td><td align="char" char="plusmn" valign="bottom">6.7 ± 0.3</td><td align="char" char="plusmn" valign="bottom">15 ± 1</td><td align="char" char="." valign="bottom">1.1</td><td align="char" char="." valign="bottom">0.3</td><td align="left" valign="bottom">D</td><td align="left" valign="bottom">R</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">S</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">G</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">N</td>	</tr><tr><td align="left" valign="bottom">iAChSnFR</td><td align="left" valign="bottom">ACh</td><td align="left" valign="bottom">ND</td><td align="char" char="." valign="bottom">12</td><td align="left" valign="bottom">ND</td><td align="char" char="." valign="bottom">1.3</td><td align="left" valign="bottom">ND</td><td align="char" char="." valign="bottom">9.2</td><td align="left" valign="bottom">I</td><td align="left" valign="bottom">V</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">H</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">T</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">G</td>	</tr><tr><td align="left" valign="bottom">iCytSnFR</td><td align="left" valign="bottom">Cytisine</td><td align="char" char="plusmn" valign="bottom">5.0 ± 0.2</td><td align="char" char="plusmn" valign="bottom">7.3 ± 0.4</td><td align="char" char="plusmn" valign="bottom">9.4 ± 0.8</td><td align="char" char="plusmn" valign="bottom">11 ± 1</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">0.7</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Y</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">W</td><td align="left" valign="bottom">-</td>	</tr><tr><td align="left" valign="bottom">iCyt_F_SnFR</td><td align="left" valign="bottom">10-Fluorocytisine</td><td align="char" char="plusmn" valign="bottom">7.9 ± 0.1</td><td align="char" char="plusmn" valign="bottom">2.3 ± 0.1</td><td align="char" char="plusmn" valign="bottom">1.4 ± 0.04</td><td align="char" char="plusmn" valign="bottom">1.6 ± 0.3</td><td align="char" char="." valign="bottom">5.6</td><td align="char" char="." valign="bottom">1.4</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">N</td><td align="left" valign="bottom">G</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">W</td><td align="left" valign="bottom">-</td>	</tr><tr><td align="left" valign="bottom">iCyt_BrEt_SnFR</td><td align="left" valign="bottom">9-Bromo-10-ethylcytisine</td><td align="char" char="plusmn" valign="bottom">4.0 ± 0.03</td><td align="char" char="plusmn" valign="bottom">3.6 ± 0.04</td><td align="char" char="plusmn" valign="bottom">5.7 ± 0.1</td><td align="char" char="plusmn" valign="bottom">4.2 ± 0.2</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">0.9</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Q</td><td align="left" valign="bottom">G</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">W</td><td align="left" valign="bottom">-</td>	</tr></tbody></table></table-wrap></sec><sec id="s2-3"><title>Specificity and thermodynamics of nicotinic iDrugSnFRs</title><p>We characterized the specificity of purified iDrugSnFRs for their drug partners versus a panel of related nicotinic agonists (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref>). The newly developed iDrugSnFRs showed some sensitivity to related nicotinic agonists. iDianiSnFR had the greatest fidelity for its drug partner but also showed an increased EC<sub>50</sub> (15 µM) as a purified protein versus its EC<sub>50</sub> in lysate (6.7 µM), possibly indicating decreased stability in a purified form. iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR showed a greater level of promiscuity for the compounds comprising the nicotinic agonist panel. Of note, iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR have an exceptionally low (60‒90 nM) EC<sub>50</sub> for varenicline. The newly developed iDrugSnFRs showed negligible binding to choline or the neurotransmitter acetylcholine, leading one to expect minimal endogenous interference during future in vivo experiments.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Dose–response relations of intensity-based drug-sensing fluorescent reporter (iDrugSnFR) protein versus a nicotinic agonist panel.</title><p>(<bold>A–D</bold>) Relevant EC<sub>50</sub> values for each iDrugSnFR are listed in <xref ref-type="table" rid="table2">Table 2</xref>. Dashed lines indicate dose–response relations that did not approach saturation for the concentration ranges tested; therefore, EC<sub>50</sub> and ∆F<sub>max</sub>/F<sub>0</sub> could not be determined. (<bold>A</bold>) iDianiSnFR shows preference for dianicline, with some promiscuity for other nicotinic agonists. (<bold>B</bold>) iCytSnFR, (<bold>C</bold>) iCyt_F_SnFR, and (<bold>D</bold>) iCyt_BrEt_SnFR bind their drug partner, but also respond to other nicotinic agonists. Ch, choline; ACh, acetylcholine; Cyt, cytisine; Diani, dianicline; Nic, nicotine; Var, varenicline; 10FC, 10-fluorocytisine; 9Br10EtC, 9-bromo-10-ethylcytisine.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Dose–response relations of nicotinic agonist intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) against select endogenous molecules.</title><p>(<bold>A</bold>) iDianiSnFR shows no fluorescent response to any of the selected endogenous molecules. (<bold>B</bold>) iCytSnFR, (<bold>C</bold>) iCyt_F_SnFR, and (<bold>D</bold>) iCyt_BrEt_SnFR show no response to any of the selected endogenous molecules except 5-HT and DA at concentrations above 100 µM. ATP, adenosine triphosphate; DA, dopamine; GABA, γ-aminobutyric acid; Glu, glutamate; Gly, glycine; Hist, histamine; L-DOPA, levodopa; NE, norepinephrine; 5-HT, serotonin.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig3-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Intensity-based drug-sensing fluorescent reporter (iDrugSnFR) dose–response relations versus a selected panel of nicotinic agonists.</title><p>ND, not determined. *, ** EC<sub>50</sub> and ∆F<sub>max</sub>/F<sub>0</sub> could not be determined from the data (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Therefore, the upper limit to the S-slope is estimated from the data at the foot of the dose–response relation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom">Drug name</th><th align="left" colspan="3" valign="bottom">iDianiSnFR</th><th align="left" colspan="3" valign="bottom">iCytSnFR</th><th align="left" colspan="3" valign="bottom">iCyt_F_SnFR</th><th align="left" colspan="3" valign="bottom">iCyt_BrEt_SnFR</th></tr><tr><th align="left" valign="bottom">ΔF<sub>max</sub>/F<sub>0</sub></th><th align="left" valign="bottom">EC<sub>50</sub> (µM)</th><th align="left" valign="bottom">S-slope</th><th align="left" valign="bottom">ΔF<sub>max</sub>/F<sub>0</sub></th><th align="left" valign="bottom">EC<sub>50</sub> (µM)</th><th align="left" valign="bottom">S-slope</th><th align="left" valign="bottom">ΔF<sub>max</sub>/F<sub>0</sub></th><th align="left" valign="bottom">EC<sub>50</sub> (µM)</th><th align="left" valign="bottom">S-slope</th><th align="left" valign="bottom">ΔF<sub>max</sub>/F<sub>0</sub></th><th align="left" valign="bottom">EC<sub>50</sub> (µM)</th><th align="left" valign="bottom">S-slope</th></tr></thead><tbody><tr><td align="left" valign="bottom">Choline</td><td align="left" valign="bottom">2.0 ± 0.1</td><td align="left" valign="bottom">84 ± 20</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">5.8 ± 0.2</td><td align="left" valign="bottom">240 ± 30</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">2.6 ± 0.1</td><td align="left" valign="bottom">18 ± 1</td><td align="left" valign="bottom">0.1</td><td align="left" valign="bottom">2.6 ± 0.1</td><td align="left" valign="bottom">12 ± 1</td><td align="left" valign="bottom">0.2</td></tr><tr><td align="left" valign="bottom">Acetylcholine</td><td align="left" valign="bottom">7.4 ± 1.0</td><td align="left" valign="bottom">660 ± 80</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">2.9 ± 0.1</td><td align="left" valign="bottom">35 ± 3</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">4.4 ± 0.3</td><td align="left" valign="bottom">222 ± 50</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">2.5 ± 0.2</td><td align="left" valign="bottom">73 ± 6</td><td align="left" valign="bottom">&lt;0.1</td></tr><tr><td align="left" valign="bottom">Cytisine</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">&lt;0.1*</td><td align="left" valign="bottom">7.3 ± 0.4</td><td align="left" valign="bottom">11 ± 1</td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">4.4 ± 0.1</td><td align="left" valign="bottom">2.6 ± 0.3</td><td align="left" valign="bottom">1.7</td><td align="left" valign="bottom">4.7 ± 0.1</td><td align="left" valign="bottom">3.5 ± 0.2</td><td align="left" valign="bottom">1.3</td></tr><tr><td align="left" valign="bottom">Dianicline</td><td align="left" valign="bottom">4.7 ± 0.2</td><td align="left" valign="bottom">15 ± 1</td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">6.5 ± 0.4</td><td align="left" valign="bottom">34 ± 4</td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">2.3 ± 0.3</td><td align="left" valign="bottom">43 ± 6</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">4–6</td><td align="left" valign="bottom">&gt;100</td><td align="left" valign="bottom">&lt;0.1**</td></tr><tr><td align="left" valign="bottom">Nicotine</td><td align="left" valign="bottom">2.2 ± 0.1</td><td align="left" valign="bottom">440 ± 100</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">6.4 ± 0.2</td><td align="left" valign="bottom">14 ± 2</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">4.7 ± 0.1</td><td align="left" valign="bottom">3.8 ± 0.2</td><td align="left" valign="bottom">1.2</td><td align="left" valign="bottom">4.8 ± 0.1</td><td align="left" valign="bottom">5.5 ± 0.2</td><td align="left" valign="bottom">0.9</td></tr><tr><td align="left" valign="bottom">Varenicline</td><td align="left" valign="bottom">2.4 ± 2.0</td><td align="left" valign="bottom">1200 ± 500</td><td align="left" valign="bottom">&lt; 0.1</td><td align="left" valign="bottom">6.5 ± 0.1</td><td align="left" valign="bottom">0.06 ± 0.01</td><td align="left" valign="bottom">110</td><td align="left" valign="bottom">7.1 ± 0.2</td><td align="left" valign="bottom">0.09 ± 0.02</td><td align="left" valign="bottom">79</td><td align="left" valign="bottom">5.3 ± 0.1</td><td align="left" valign="bottom">0.06 ± 0.01</td><td align="left" valign="bottom">88</td></tr><tr><td align="left" valign="bottom">10-Fluorocytisine</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">2.3 ± 0.1</td><td align="left" valign="bottom">1.6 ± 0.3</td><td align="left" valign="bottom">1.4</td><td align="left" valign="bottom">3.0 ± 0.1</td><td align="left" valign="bottom">4.7 ± 0.3</td><td align="left" valign="bottom">0.6</td></tr><tr><td align="left" valign="bottom">9-Bromo-10-ethylcytisine</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">ND</td><td align="left" valign="bottom">3.1 ± 0.1</td><td align="left" valign="bottom">31 ± 2</td><td align="left" valign="bottom">0.1</td><td align="left" valign="bottom">3.6 ± &lt; 0.1</td><td align="left" valign="bottom">4.2 ± 0.2</td><td align="left" valign="bottom">0.9</td></tr></tbody></table></table-wrap><p>We also performed dose–response experiments with iDianiSnFR, iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR against a panel of nine endogenous molecules, including neurotransmitters (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). iDianiSnFR showed no response to any of the nine selected compounds above background. iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR showed no response above background for seven of the compounds. However, they exhibited a ΔF/F<sub>0</sub> of 0.25‒0.8 to dopamine at 316 µM/1 mM and a ΔF/F<sub>0</sub> of 0.8–1.5 to serotonin (5-HT) at 316 µM/1 mM. In terms of S-slope, the relevant metric for most cellular or in vivo experiments, the SnFRs are at least 250-fold more sensitive to their eponymous partners than to other molecules we have tested.</p><p>To examine the thermodynamics of the iDrugSnFR:drug interaction, we conducted isothermal titration calorimetry (ITC) binding experiments (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The experimentally determined K<sub>D</sub> of each iDrugSnFR:drug pair using ITC was within a factor of 1.5 from the experimentally determined EC<sub>50</sub> for fluorescence in <italic>E. coli</italic> lysate or purified protein (<xref ref-type="table" rid="table3">Table 3</xref>). We infer that the EC<sub>50</sub> for fluorescence is dominated by the overall binding of the ligand for all the iDrugSnFRs.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Isothermal titration calorimetry traces, fits, and thermodynamic data.</title><p>Top row: exemplar heat traces of iCytSnFR, iCyt_F_SnFR, iCyt_BrEt_SnFR, and iDianiSnFR paired with their drug partners obtained by isothermal calorimetry. The heats for iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR were exothermic, while that for iDianiSnFR was endothermic. Middle row: the resulting fits for each iDrugSnFR:drug pair from the integrated heats comprising each series of injections. Bottom row<bold>:</bold> energy calculations. All iDrugSnFRs show exergonic reactions, but the relative enthalpic and entropic contributions vary among iDrugSnFRs. Data are from three separate runs, mean ± SEM. iDrugSnFR, intensity-based drug-sensing fluorescent reporter.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig4-v2.tif"/></fig><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Affinity, occupancy number, and thermodynamic data calculated from isothermal titration calorimetry.</title><p>Data are the mean ± SEM, three runs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Biosensor</th><th align="left" valign="bottom">K<sub><bold>D</bold></sub> (μM)</th><th align="left" valign="bottom">n</th><th align="left" valign="bottom">ΔH(kcal/mol)</th><th align="left" valign="bottom">-TΔS(kcal/mol)</th><th align="left" valign="bottom">ΔG(kcal/mol)</th></tr></thead><tbody><tr><td align="left" valign="bottom">iCytSnFR</td><td align="char" char="plusmn" valign="bottom">13.7 ± 1.1</td><td align="char" char="plusmn" valign="bottom">0.84 ± 0.05</td><td align="char" char="plusmn" valign="bottom">–2.1 ± 0.1</td><td align="char" char="plusmn" valign="bottom">–4.6 ± 0.2</td><td align="char" char="plusmn" valign="bottom">–6.6 ± 0.1</td></tr><tr><td align="left" valign="bottom">iCyt_F_SnFR</td><td align="char" char="plusmn" valign="bottom">1.8 ± 0.5</td><td align="char" char="plusmn" valign="bottom">0.83 ± 0.02</td><td align="char" char="plusmn" valign="bottom">–5.5 ± 0.1</td><td align="char" char="plusmn" valign="bottom">–2.4 ± 0.2</td><td align="char" char="plusmn" valign="bottom">–7.9 ± 0.1</td></tr><tr><td align="left" valign="bottom">iCyt_BrEt_SnFR</td><td align="char" char="plusmn" valign="bottom">5.4 ± 0.8</td><td align="char" char="plusmn" valign="bottom">0.69 ± 0.09</td><td align="char" char="plusmn" valign="bottom">–1.12 ± 0.03</td><td align="char" char="plusmn" valign="bottom">6.1 ± 0.1</td><td align="char" char="plusmn" valign="bottom">–7.2 ± 0.1</td></tr><tr><td align="left" valign="bottom">iDianiSnFR</td><td align="char" char="plusmn" valign="bottom">7.6 ± 1.4</td><td align="char" char="plusmn" valign="bottom">0.92 ± 0.02</td><td align="char" char="plusmn" valign="bottom">3.2 ± 0.5</td><td align="char" char="plusmn" valign="bottom">10.1 ± 0.4</td><td align="char" char="plusmn" valign="bottom">–7.0 ± 0.2</td></tr></tbody></table></table-wrap></sec><sec id="s2-4"><title>Kinetics of nicotinic agonist iDrugSnFRs: Stopped-flow</title><p>In a stopped-flow apparatus, we measured the fluorescence changes of iDrugSnFRs with millisecond resolution during multiple 1 s trials and an independent 100 s trial. The stopped-flow data revealed that iDrugSnFRs do not have pseudo-first-order kinetic behaviors typical of two-state binding interactions. Time courses of iDianiSnFR (both over 1 s and 100 s) were best fitted by double exponential equations. Most of the fluorescence change occurs within the first 0.1 s of mixing (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), with only minor additional increase by 100 s.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Stopped-flow fluorescence kinetic data for (<bold>A</bold>) iDianiSnFR, (<bold>B</bold>) iCytSnFR, (<bold>C</bold>) iCyt_F_SnFR, and (<bold>D</bold>) iCyt_BrEt_SnFR over 1 s and 100 s.</title><p>Fluorescence was activated by mixing with the agonists as noted. Stopped-flow data shows a departure from first-order kinetics for this set of intensity-based drug-sensing fluorescent reporter (iDrugSnFRs). iDianiSnFR and iCyt_F_SnFR are fit to a double exponential; iCytSnFR and iCyt_BrEt_SnFR are fit to a single exponential. (<bold>E–H</bold>) Plots of the observed apparent rate constant against [agonist] for the 1 s data obtained in (<bold>A–D</bold>). In (<bold>H</bold>), we have confidence that the k<sub>obs</sub> shows a maximal value of 40–50 s<sup>–1</sup>; the K<sub>d</sub> probably lies within twofold of the fitted value.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig5-v2.tif"/></fig><p>Changes in fluorescence from iCytSnFR during the first 1 s of mixing fit well to a single exponential (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) and have close to pseudo-first-order kinetics (i.e., the observed rate of fluorescence change is nearly linear with drug concentration). As with iDianiSnFR, most of the fluorescence change occurs within the first second, with additional fluorescent increase continuing over the next minute (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, right panel).</p><p>Like iDianiSnFR, iCyt_F_SnFR fluorescence changes are best fit by a double exponential (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), but the time course of fluorescence change is significantly slower. Fluorescence gradually increases throughout the recording period and beyond. This information was considered in later in vitro and ex vivo experiments. iCyt_BrEt_SnFR fits well to a single exponential (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) for the first 1 s of data collection, but like the other sensors, continues to increase its fluorescence over longer periods.</p><p>We plotted the k<sub>obs</sub> (s<sup>–1</sup>) obtained in the 1 s stopped-flow experiments versus concentration (<xref ref-type="fig" rid="fig5">Figure 5E–H</xref>) (see also <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). The aberrations from ideal first-order kinetics vitiate generation of definitive k<sub>off</sub> and k<sub>on</sub> values but we can approximate a K<sub>max</sub> and K<sub>D</sub> from our fitting procedures. Our stopped-flow experiments reinforced previous observations (<xref ref-type="bibr" rid="bib58">Unger et al., 2020</xref>) that the kinetics of iDrugSnFR binding involve complexities beyond a simple first-order kinetic model governing two binding partners.</p></sec><sec id="s2-5"><title>Kinetics of nicotinic agonist iDrugSnFRs: Millisecond microperfusion</title><p>We also studied iCytSnFR_PM expressed in HEK293T cells during fluorescence responses to ACh, cytisine, or varenicline in a microperfusion apparatus that exchanged solutions near the cell on a millisecond time scale (Materials and methods). This system directly measures the decay of the response when ligand is suddenly removed. The rank order of the iCytSnFR steady-state sensitivities is varenicline &gt; cytisine &gt; ACh. The time constant for decay decreased with increasing steady-state EC<sub>50</sub> of the ligands, as though more tightly binding ligands dissociate more slowly (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Decay of the iCytSnFR_PM responses after removal of ACh, cytisine, or varenicline.</title><p>(<bold>A</bold>) The red, blue, and black traces are mean ΔF/F<sub>0</sub> values for the ACh (200 µM), cytisine (15 µM), and varenicline (2 µM) responses as a function of time (n = 4–10 areas per ligand). The ΔF/F<sub>0</sub> was normalized to the peak response for each ligand. Sampling rate was 5 frames/s. Ligand was applied for 5 s, denoted by the black horizontal bar above the traces. (<bold>B–D</bold>) Examples of the decay phase of the response to ACh (200 µM), cytisine (15 µM), and varenicline (2 µM) in individual areas (black traces in each panel). Red lines are fits to the sum of one or two negative exponential terms and a constant (red lines in each panel) using nonlinear least-squares regression. (<bold>B</bold>) The decay of the ACh (200 µM) response (n = 1 area, 3 cells) was monophasic with a single time constant (τ<sub>0ff</sub>) of 0.61 ± 0.02 s (± SE, n = 86 frames, sampling rate of 9.8 frames/s). The red line is a fit to the sum of a negative exponential component (R<sup>2</sup> of 0.98). (<bold>C</bold>) The decay of the cytisine (15 µM) response (n = 1 area, four cells) was biphasic with time constants (τf<sub>off</sub>, τs<sub>off</sub>) of 1.9 ± 0.2 and 6.6 ± 0.5 s (n = 149 frames, sampling rate of 5 frames/s). The red line is a fit to the sum of two negative exponential components and a constant (R<sup>2</sup> of 0.996). It was significantly better than that of the sum of a single negative exponential term and a constant (F-test, p&lt;0.05). The relative amplitude of the slower decay component (A<sub>s</sub>/(A<sub>s</sub>+ A<sub>f</sub>), where A<sub>s</sub> is amplitude of the slower component of decay in units of ΔF/F<sub>0</sub> and A<sub>f</sub> is amplitude of the faster component) was 61%. Inset: neither rate constant changed significantly over the [cytisine] range from 5 to 15 μM. Dashed lines give the average over this range. (<bold>D</bold>) The decay of the varenicline (2 µM) response (n = 1 area, three cells) was also biphasic with a τf<sub>off</sub> and τs<sub>off</sub> of 9 ± 1 s and 150 ± 10 s (n = 178 frames, sampling rate of 1 frame/s), respectively. The A<sub>s</sub>/(A<sub>s</sub>+ A<sub>f</sub>) was 83%. The red line is a fit to the sum of two negative exponential terms and a constant (R<sup>2</sup> of 0.994), and it was significantly better than that to the sum of a single negative exponential term and a constant (F-test, p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig6-v2.tif"/></fig><p>We measured the decay waveforms after drug pulses at concentrations ≥ the EC<sub>50</sub> of the steady-state response to maximize the ΔF/F<sub>0</sub> signal/noise ratio (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>). Because the decay phases are measured in zero [ligand], one expects that the decay rate constant(s) (k<sub>off</sub>) for an iDrugSnFR do not depend on the pulsed ligand concentration. Decay of the ACh response followed a single exponential time course (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The values of the k<sub>off</sub> for 30, 100, and 200 µM ACh did not differ significantly (ANOVA, p=0.62, degrees of freedom [df] = 2 (model), 20 [error]). We pooled them to obtain a mean k<sub>off</sub> of 1.9 ± 0.1 s<sup>–1</sup> (mean ± SEM, n = 23 areas [50 cells]). The corresponding time constant τ<sub>0ff</sub> was 530 ± 30 ms. Hence, the temporal resolution of the CytSnFR_PM sensor for changes in the ACh concentration was in the subsecond range.</p><p>The decay of the cytisine and varenicline response was biphasic (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>): two exponential decay terms with an additional constant component fitted the cytisine decay significantly better than a single exponential term (F-test, p&lt;0.05). As expected, neither the faster decay rate constants (kf<sub>off</sub>) (ANOVA, p=0.30, df = 3,32) nor the slower decay rate constants (ks<sub>off</sub>) (ANOVA, p=0.54, df = 3,31) differed among the tested cytisine concentrations (5–15 µM). The kf<sub>off</sub> and ks<sub>off</sub> for 5–15 µM cytisine were 0.61 ± 0.04 s<sup>–1</sup> (n = 36 areas, 105 cells) and 0.146 ± 0.006 s<sup>–1</sup> (n = 35 areas, n = 103 cells), respectively. The corresponding decay time constants (τf<sub>0ff</sub>, τs<sub>0ff</sub>) were 1.8 ± 0.1 s and 6.9 ± 0.2 s. Therefore, the temporal resolution of CytSnFR_PM sensor for cytisine was &lt;10 s, adequate for the temporal resolution of the live-cell experiments presented below.</p><p>Interestingly, the decay waveform of the varenicline response was much slower than that for cytisine or ACh (<xref ref-type="fig" rid="fig6">Figure 6A and D</xref>). We pulsed 2 µM varenicline, &gt;&gt; the EC<sub>50</sub> of the steady-state response of the isolated protein (60 ± 10 nM) (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). The values of the kf<sub>off</sub> and ks<sub>off</sub> were 0.9 ± 0.2 s<sup>–1</sup> and 0.0065 ± 0.0002 s<sup>–1</sup>, respectively (n = 4 areas [nine cells]). The slower component dominated the decay phase, with a fractional amplitude of 85% ± 1%. Thus, the temporal resolution of the iCytSnFR_PM sensor for varenicline was in the minute range. In the live-cell experiments described below, it would not be possible to resolve the differences between varenicline at the PM and in the ER. The relatively high affinity of iCytisineSnFR for varenicline, which presumably arises in part from the increased lifetime of the varenicline-iDrugSnFR complex, has drawbacks. The temporal resolution of iNicSnFR3a and iNicSnFR3b, which bind varenicline ~100-fold less tightly, is appropriate for subcellular experiments (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). The previous experiments showing ER entry of varenicline used iNicSnFR3a and iNicSnFR3b (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). For additional microperfusion data and analyses, see <xref ref-type="fig" rid="app2fig1">Appendix 2—figures 1</xref>–<xref ref-type="fig" rid="app2fig3">3</xref>.</p></sec><sec id="s2-6"><title>Characterization of nicotinic iDrugSnFRS in HeLa cells and primary mouse hippocampal culture</title><p>We examined the subcellular pharmacokinetics of the nicotinic agonists in mammalian cell lines and primary mouse hippocampal neurons. The nicotinic iDrugSnFRs were targeted to the PM (iDrugSnFR_PM) or the ER (iDrugSnFR_ER) as previously described (<xref ref-type="bibr" rid="bib4">Bera et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). We then performed a dose–response experiment using wide-field fluorescence imaging with each iDrugSnFR and its drug partner, sampling a range of concentrations covering a log scale surrounding the EC<sub>50</sub> as determined for the purified protein (<xref ref-type="fig" rid="fig7">Figures 7</xref> and <xref ref-type="fig" rid="fig8">8</xref>, <xref ref-type="video" rid="video3">Videos 3</xref>–<xref ref-type="video" rid="video6">6</xref>). iDianiSnFR showed a robust response to dianicline at the PM and the ER in HeLa cells across a range of concentrations (3.125‒100 µM), and the speed was nearly limited by solution exchanges; there was a clear return to baseline fluorescence upon washout on the order of seconds after each drug application. At 100 µM, the PM and ER have a ΔF/F<sub>0</sub> of ~1.2, but at lower concentrations, the ER displayed 30–75% of the signal detected at the PM, which may indicate a difference in membrane crossing (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Imaging in primary mouse hippocampal neurons demonstrated a similar trend (<xref ref-type="fig" rid="fig8">Figure 8A</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Nicotinic agonist intensity-based drug-sensing fluorescent reporter (iDrugSnFR) dose–response relations in HeLa cells.</title><p>(<bold>A–D</bold>) Each iDrugSnFR detects its drug partner at the plasma membrane (PM) and endoplasmic reticulum (ER) of HeLa cells at the concentrations sampled. BC, buffer control. SEM of data are indicated by semi-transparent shrouds around traces where trace width is exceeded. (<bold>A</bold>) iDianiSnFR detects dianicline with a return to baseline fluorescence between drug applications. (<bold>B</bold>) iCytSnFR detection at the PM returns to baseline fluorescence between applications, while detection at the ER shows incomplete wash-in and washout. (<bold>C</bold>) iCyt_F_SnFR fluorescence response to the presence of 10-fluorocytisine in the ER also shows an incomplete washout between applications. (<bold>D</bold>) iCyt_BrEt_SnFR detects 9-bromo-10-ethylcytisine with wash-in and washout fluorescence similar to the pattern seen in iDianiSnFR.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Traces of fluorescence responses during time-resolved low-concentration dose–response relations for nicotinic agonists in HeLa cells.</title><p>BC, buffer control. SEM of data are indicated by semi-transparent shrouds around traces where trace width is exceeded. Cyt (cytisine) in cells expressing iCytSnFR_ER (<bold>A</bold>) or iCytSnFR_PM (<bold>B</bold>); 10FC (10-fluorocytisine) in cells expressing iCyt_F_SnFR_ER (<bold>A</bold>) or iCyt_F_SnFR_PM (<bold>B</bold>); 9Br10EtC (9-bromo-10-ethylcytisine) in cells expressing iCyt_BrEt_SnFR_ER (<bold>A</bold>) or iCyt_BrEt_SnFR_PM (<bold>B</bold>). Relatively long (300 s) washout periods between drug applications allowed a return to baseline fluorescence for the (<bold>A</bold>) endoplasmic reticulum (ER) and (<bold>B</bold>) plasma membrane (PM). (<bold>C</bold>) A zoomed-in exemplar comparison of the ER and PM for a pulse of 1 µM 10-fluorocytisine shows a distinct lag in the decrease of the fluorescent signal in the ER as compared to the PM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Dose–response relations for iCytSnFR and iCyt_F_SnFR against nicotine in HeLa cells.</title><p>BC, buffer control. SEM of data are indicated by semi-transparent shrouds around traces where trace width is exceeded. (<bold>A</bold>) iCytSnFR and (<bold>B</bold>) iCyt_F_SnFR detect nicotine at both the plasma membrane (PM) and endoplasmic reticulum (ER). Nicotine enters and exits the ER rapidly over seconds, a direct contrast to the behavior of cytisine and 10-fluorocytisine as detected by their intensity-based drug-sensing fluorescent reporter (iDrugSnFR) partners.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig7-figsupp2-v2.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Spinning disk laser scanning confocal inverted microscope images of nicotinic agonist intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) in HeLa cells.</title><p>Endoplasmic reticulum (ER)-targeted constructs of iDianiSnFR, iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR are shown before (<bold>A1–D1</bold>) and during (<bold>A2–D2</bold>) exposure to each drug partner. ER-targeted iDrugSnFRs show the reticulated ER and dark ovals corresponding to the nucleus. Plasma membrane (PM)-targeted constructs of the same iDrugSnFRs are shown before (<bold>E1–H1</bold>) and after (<bold>E2–H2</bold>) drug introduction. Localization to the PM is robust, with some minimal puncta that may represent inclusion bodies or internal transport.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig7-figsupp3-v2.tif"/></fig></fig-group><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Nicotinic agonist intensity-based drug-sensing fluorescent reporter (iDrugSnFR) dose–response experiments in mouse primary hippocampal neurons transduced with AAV9-hSyn iDrugSnFR.</title><p>Cultured primary mouse hippocampal neurons were transduced with endoplasmic reticulum (ER)- or plasma membrane (PM)-targeted constructs. BC, buffer control. SEM of data are indicated by semi-transparent shrouds around traces where trace width is exceeded. (<bold>A–D</bold>) Each iDrugSnFR detects its drug partner at the PM and ER over the concentrations sampled. (<bold>A</bold>) iDianiSnFR detects dianicline with a return to baseline fluorescence between drug applications. (<bold>B</bold>) iCytSnFR detection at the PM returns to baseline fluorescence between applications, while detection at the ER shows an incomplete washout. (<bold>C</bold>) iCyt_F_SnFR fluorescence response to the presence of 10-fluorocytisine in the ER also shows an incomplete washout between applications. (<bold>D</bold>) iCyt_BrEt_SnFR_ER detects 9-bromo-10-ethylcytisine with a wash-in and decay intermediate between iDianiSnFR and the other two cytisine derivatives.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Spinning disk laser scanning confocal inverted microscope images of nicotinic agonist intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) in primary mouse hippocampal neurons.</title><p>Endoplasmic reticulum (ER)-targeted constructs of iDianiSnFR, iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR are shown before (<bold>A1–D1</bold>) and during (<bold>A2–D2</bold>) exposure to each drug partner. ER-targeted iDrugSnFRs show the reticulated the ER and dark ovals corresponding to the nucleus. Plasma membrane (PM)-targeted constructs of the same iDrugSnFRs are shown before (<bold>E1–H1</bold>) and after (<bold>E2–H2</bold>) drug introduction. Localization in the PM is robust, with some minimal puncta that may represent inclusion bodies or internal transport.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-fig8-figsupp1-v2.tif"/></fig></fig-group><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-74648-video3.mp4"><label>Video 3.</label><caption><title>iDianiSnFR_ER dose-response relations in HeLa cells.</title><p>The dianicline concentrations are shown. The scale bar is shown. The video is 25-fold faster than real time.</p></caption></media><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-74648-video4.mp4"><label>Video 4.</label><caption><title>iDianiSnFR_PM dose-response relations in HeLa cells.</title><p>The dianicline concentrations are shown. The scale bar is shown.The video is 25-fold faster than real time.</p></caption></media><media id="video5" mime-subtype="mp4" mimetype="video" xlink:href="elife-74648-video5.mp4"><label>Video 5.</label><caption><title>iCytSnFR_ER dose-response relations in HeLa cells.</title><p>The cytisine concentrations are shown. The scale bar is shown. The video is 25-fold faster than real time.</p></caption></media><media id="video6" mime-subtype="mp4" mimetype="video" xlink:href="elife-74648-video6.mp4"><label>Video 6.</label><caption><title>iCytSnFR_PM dose-response relations in HeLa cells.</title><p>The cytisine concentrations are shown. The scale bar is shown. The video is 25-fold faster than real time.</p></caption></media><p>Cytisine showed slower entry into and exit from the ER of HeLa cells. The iCytSnFR_PM construct detected cytisine at concentrations from 0.078 to 80 µM and demonstrated a return to baseline fluorescence upon washout on the order of seconds after each drug application, reaching a maximum ΔF/F<sub>0</sub> of ~2 at concentrations above 5 µM (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). In contrast to the _PM construct, the iCytSnFR_ER construct only detected cytisine with a ΔF/F<sub>0</sub> above the buffer control in the range of concentrations from 1.25 to 80 µM with a ΔF/F<sub>0</sub>, which was 25–50% of the maximum ΔF/F<sub>0</sub> detected at the PM. Additionally, in the range of detectable concentrations of cytisine, the washout of cytisine was much slower than solution changes (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). The incomplete washout persists even after several minutes and corresponds with previous suggestions that cytisine has low membrane permeability, as evidenced by its low brain penetration (<xref ref-type="bibr" rid="bib46">Rollema et al., 2010</xref>).</p><p>In primary mouse hippocampal neurons, iCytSnFR detection of cytisine exhibited the same kinetic trends seen in HeLa cell experiments (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). During cytisine application (60 s) from 0.078 to 80 µM, the iCytSnFR_PM fluorescence nearly reached a plateau, and during the washout (90–180 s), the fluorescence decayed back to baseline, though the decay slowed after removal of higher [cytisine]. The _PM construct reached a maximum ΔF/F<sub>0</sub> of ~1.25 at 80 µM, which was approximately 60% of the signal observed in HeLa cell experiments (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). The iCytSnFR_ER detection of cytisine in the ER reflected the trends seen in HeLa cells, with incomplete cytisine wash-in phases and prolonged cytisine washout phases. One observable difference was that the maximum ΔF/F<sub>0</sub> (~1.25) of iCytSnFR_ER reached a similar maximum to that of iCytSnFR_PM in neurons, which was not observed in HeLa cell experiments (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><p>In preliminary HeLa cell experiments with varenicline applied to iCytSnFR, we found much slower kinetics that differed little between the _ER and _PM constructs (data not shown). These findings, which vitiated the use of the iCytSnFR-varencline pair in the cellular experiments, are consistent with the markedly slow kinetics of varenicline-iCytSnFR interactions in the microperfusion experiments (see above).</p><p>iCyt_F_SnFR targeted to the PM and ER showed characteristics similar to iCytSnFR in HeLa cells. The _PM construct detected 10-fluorocytisine across a range of concentrations with a return to baseline fluorescence between applications, while the _ER construct detected 10-fluorocytisine with ΔF/F<sub>0</sub> values that were only 25–33% of those detected at the PM (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Similar to the iCytSnFR_ER detection of cytisine, the iCyt_F_SnFR_ER detection of 10-fluorocytisine was much slower than solution changes and did not return to baseline between applications, though the washout occurs on the order of minutes, rather than tens of minutes as with iCytSnFR_ER (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). The difference in PM and ER detection of 10-fluorocytisine again shows decreased membrane permeability into HeLa cells compared to other drugs we have examined with other iDrugSnFRs. Overall, the detection of 10-fluorocytisine with iCyt_F_SnFR in primary hippocampal culture resembled our data with iCyt_F_SnFR in HeLa cells. Nevertheless, there were distinct differences (<xref ref-type="fig" rid="fig8">Figure 8C</xref>), such as a decreased maximum ΔF/F<sub>0</sub> in the iCyt_F_SnFR_PM construct and a similar maximum ΔF/F<sub>0</sub> of ~1 for both the _ER and _PM constructs. Additionally, the decay of the iCyt_F_SnFR responses lasted tens of minutes, resembling the iCytSnFR_ER data in primary hippocampal culture.</p><p>9-Bromo-10-ethylcytisine showed a kinetic profile resembling dianicline. iCyt_BrEt_SnFR_PM responses to 9-bromo-10-ethylcytisine (0.1‒31.6 µM) were nearly limited by solution exchanges with a return to baseline fluorescence on the order of seconds, and a maximum ΔF/F<sub>0</sub> of ~1.5 at 31.6 µM. iCyt_BrEt_SnFR_ER also detected 9-bromo-10-ethylcytisine over this range of concentrations and returned to baseline fluorescence between applications (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). ΔF/F<sub>0</sub> values for iCyt_BrEt_SnFR_ER were 50–75% of the ΔF/F<sub>0</sub> values detected by iCyt_BrEt_SnFR_PM, which indicated that 9-bromo-10-ethylcytisine crossed into and out of cells readily (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Imaging in primary mouse hippocampal neurons revealed the same trend (<xref ref-type="fig" rid="fig8">Figure 8D</xref>).</p><p>To more fully examine the membrane-crossing properties of the nicotinic agonists, we recorded the fluorescence waveforms for several drugs at concentrations between 0.1 and 3.16 µM with much longer application times and washout times than in the above experiments (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). With these conditions, the fluorescence signals suggested complete washout of each nicotinic agonist from the ER of HeLa cells. However, it is noteworthy that even when applied at concentrations as low as 0.1 µM and 0.316 µM, cytisine and 10-fluorocytisine require washout times of several minutes from the ER. In contrast, the iDrugSnFR localized to the PM shows a rapid return to baseline after drug application.</p><p>Because the data of <xref ref-type="fig" rid="fig7">Figures 7B</xref> and <xref ref-type="fig" rid="fig8">8B</xref> indicated that iCytSnFR_PM functions as expected from stopped-flow and millisecond perfusion, we applied additional experiments to ensure that our observations of drug entry and exit from the ER were not the result of idiosyncratic biosensor function or folding in the ER. iCytSnFR and iCyt_F_SnFR both bind nicotine in the same concentration range as cytisine (though with lower ΔF/F<sub>0</sub>). After transfection of _PM and _ER constructs for each sensor into HeLa cells, we performed time-resolved imaging for pulses of 0.1–31.6 µM nicotine (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). These nicotine waveforms resembled those already published with iNicSnFR3a and iNicSnFR3b (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>), confirming that iCytSnFR_ER functions as expected with a more permeant nicotinic drug. Thus, the slower kinetics for iCytSnFR_ER with cytisine and iCyt_F_SnFR_ER with 10-fluorocytisine arise because these drugs cross membranes more slowly.</p><p>To examine localization of the _PM and _ER constructs at higher optical resolution, we imaged HeLa cells and primary mouse hippocampal culture using a spinning disk laser scanning inverted confocal microscope. As previously observed, ER-targeted iDrugSnFR was retained in the ER (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). The iDrugSnFR constructs targeted to the PM showed correct localization, with some iDrugSnFR observed in the cell interior (most likely as part of the cellular membrane trafficking system; <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>).</p><p>Several complexities in the HeLa cell and neuron experiments imposed uncertainties on our kinetic analyses. These complexities include the limitations of solution changes, diffusion within cytoplasm, unknown mixing at the surface facing the coverslip, and corrections for baseline drift due to bleaching. We restrict the quantitative comparisons to the estimate that cytisine and 10-fluorocytisine cross the membrane &gt;30-fold more slowly than the other drugs tested.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Membrane permeation of molecules with low logD<sub>pH7.4</sub></title><p>The experiments show, to our knowledge, the first time-resolved measurements of membrane permeation for drugs in the logD<sub>pH7.4</sub> range less than –1. Most orally available drugs have logD<sub>pH7.4</sub> values between 2 and 4 (<xref ref-type="bibr" rid="bib52">Smith et al., 2012</xref>). Cytisine, varenicline, dianicline, and the cytisine analogs studied here have calculated membrane partition coefficients some 3–6 orders of magnitude lower. These values and their order vary according to the algorithm, partially because of uncertainties in predicting pK<sub>a</sub> (<xref ref-type="bibr" rid="bib42">Pieńko et al., 2016</xref>); here, we provide values calculated by Chemicalize (see Materials and methods): 10-fluorocytisine, –2.70; cytisine, –2.64; dianicline, –1.29; varenicline, –1.27; 9-bromo-10-ethylcytisine, –1.13. It is remarkable that drugs with such low calculated partition coefficients do cross membranes on a time scale of seconds (9-bromo-10-ethylcytisine, varenicline, dianicline) to minutes (10-fluorocytisine, cytisine). According to some (but not all) algorithms, the calculated logD<sub>pH7.4</sub> values fall in the same two classes as the measured kinetics of membrane permeability: 10-fluorocytisine and cytisine are the slowest, and only these two agonists have logD<sub>pH7.4</sub> values &lt; –2. These observations support previous work suggesting that differences among chemical properties of nicotinic partial agonists correlate with drug permeation into the cerebrospinal fluid (CSF) after peripheral administration in mice (<xref ref-type="bibr" rid="bib46">Rollema et al., 2010</xref>).</p></sec><sec id="s3-2"><title>The iDrugSnFR paradigm</title><p>The iDrugSnFRs are sensitive enough to allow experiments near the experimentally determined (or otherwise projected) concentration in the human blood and CSF (<xref ref-type="bibr" rid="bib2">Astroug et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Jeong et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Rollema et al., 2010</xref>). The iDrugSnFRs have the advantage that they measure free aqueous ligand concentration (‘activity’), as sensed by nAChRs. Targeting sequences provide for visualization within the lumen of organelles – here, the ER.</p><p>The experiments do not use radiolabeled drugs, in vivo microdialysis or other experiments on live animals, or mass spectrometry-liquid chromatography instruments. Once protein design has given an entry into a class of iDrugSnFRs, straightforward optimization at the binding site produces the desired, selective iDrugSnFRs for individual molecules. For drugs that bind at orthosteric cholinergic sites (both nicotinic and muscarinic), we anticipate that a collection of tens, rather than hundreds, of iDrugSnFRs will suffice to detect all present and future ligands. The experiments use standard, modest-power fluorescence microscopes. Cultured cell lines yield data comparable to cultured neurons.</p><p>We comment on varenicline. None of the biosensors in <xref ref-type="table" rid="table1">Table 1</xref> were evolved to bind varenicline; yet it binds to some iDrugSnFRs with nanomolar EC<sub>50</sub>. Only iDianiSnFR, which lacks His68, binds varenicline with EC<sub>50</sub> &gt; 10 μM. Even tighter binding has been achieved with varenicline derivatives at mutated ligand-gated channels (<xref ref-type="bibr" rid="bib32">Magnus et al., 2019</xref>). On the one hand, the cellular experiments described here cannot use iDrugSnFR pairs with dissociation rate constants less than ~0.1 s<sup>–1</sup>, corresponding to an EC<sub>50</sub> of less than ~100 nM. On the other hand, all known neural drugs leave the human body and brain much more slowly, with rates determined primarily by metabolism; even ‘fast’ nicotine metabolizers display time constants of ~1200 s (<xref ref-type="bibr" rid="bib14">Dempsey et al., 2004</xref>). Highly sensitive, tightly binding, reagentless iDrugSnFRs will be used in studies on personal pharmacokinetics in biofluids.</p></sec><sec id="s3-3"><title>Structure–function relations for nicotinic and other iDrugSnFRs</title><p>This study shows that the amine group of nicotinic ligands makes equidistant cation-π interactions with two tyrosine residues (Tyr65, Tyr357), and this is confirmed by higher-resolution (1.5–1.7 Å) structures of varenicline, acetylcholine, and choline crystallized with isolated PBP moieties (PDB 7S7X, SV1R, 7S7Z, respectively; see also 3R6U, 6EYQ, and 3PPQ). Cation-π interactions also occur for cholinergic and/or nicotinic ligands in nAChRs (<xref ref-type="bibr" rid="bib37">Morales-Perez et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Post et al., 2017</xref>), the acetylcholine-binding protein (<xref ref-type="bibr" rid="bib8">Celie et al., 2004</xref>), PBPs (<xref ref-type="bibr" rid="bib50">Schiefner et al., 2004</xref>), and muscarinic receptors (<xref ref-type="bibr" rid="bib21">Haga et al., 2012</xref>). We also observe that the protonated amine of varenicline makes a hydrogen bond to a backbone carbonyl group, another similar theme in acetylcholine binding protein (<xref ref-type="bibr" rid="bib8">Celie et al., 2004</xref>) and nAChRs (<xref ref-type="bibr" rid="bib60">Xiu et al., 2009</xref>).</p><p>This study presents a general step forward in understanding the structure–function relations of iDrugSnFRs. The chromophore in the cpGFP moiety of most present iDrugSnFRs (this paper, iGluSnFR, iSeroSnFR) contains a tyrosine in an extended π system (<xref ref-type="bibr" rid="bib40">Ormö et al., 1996</xref>; <xref ref-type="bibr" rid="bib56">Tsien, 1998</xref>). The photophysics of the chromophore depends strongly on the surrounding water molecules and side chains (<xref ref-type="bibr" rid="bib7">Brejc et al., 1997</xref>; <xref ref-type="bibr" rid="bib56">Tsien, 1998</xref>). We found that Glu78 in Linker 1 changes its orientation: in the liganded state, it interacts with two positively charged residues (Lys97 and Arg99) on the surface of the cpGFP; and in the apo state, Glu78 has moved ~14 Å to form a hydrogen bonding interaction with the tyrosine moiety of the chromophore. Presumably the liganded state of iNicSnFR3adt allows for a water molecule to hydrogen bond with the hydroxy group of the chromophore, promoting its fluorescence; but this water molecule is replaced by protonated Glu78 in the unliganded state, which leads to nonfluorescent state of cpGFP, as suggested by <xref ref-type="bibr" rid="bib38">Nasu et al., 2021</xref>.</p><p>While we cannot resolve the protonation-deprotonation event, the available functional data show good support for its occurrence, as follows. (1) The apo form of the iDrugSnFR increases its F<sub>0</sub> by 10-fold per pH unit (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>), as though when deprotonated, Glu78 leaves the ‘candle snuffer’ position and moves to make the salt bridges with Lys97 and Arg99. (2) The EC<sub>50</sub> for the ligand decreases by 10-fold per pH unit (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>), as though the conformation of the linker that forms the salt-bridge form is also the closed, liganded, fluorescent form of the PBP. Other observations favor the crucial role of the Glu78–chromophore interaction. (3) Only glutamate functions in position 78 of iSeroSnFR (<xref ref-type="bibr" rid="bib58">Unger et al., 2020</xref>). (4) The mTurquoise variant in iGluSnFR, which has a tryptophan chromophore, requires entirely different linkers (<xref ref-type="bibr" rid="bib35">Marvin et al., 2018</xref>).</p></sec><sec id="s3-4"><title>Challenges at the intersection of pharmaceutical science and nicotine addiction science</title><p>Our measurements show that nicotinic ligands with logD<sub>pH7.4</sub> &lt; ~–2 cross membranes much more slowly than do ligands with logD<sub>pH7.4</sub> &gt; ~–2. These measurements have two, possibly opposing, implications for future smoking-cessation drugs. On the one hand, α4β2 agonists that enter the ER, like nicotine and varenicline, upregulate nAChRs (<xref ref-type="bibr" rid="bib57">Turner et al., 2011</xref>), which may be necessary and sufficient for addiction (<xref ref-type="bibr" rid="bib22">Henderson and Lester, 2015</xref>); and maintenance of upregulation by varenicline may help to explain its suboptimal quit rate. On the other hand, ligands that do not enter the ER are also unlikely to enter the brain and therefore unlikely to be useful for smoking cessation.</p><p>Smoking-cessation drugs must also contend with other ER-based processes. (1) Most drug metabolism takes place in the ER and (2) upregulation occurs at a sustained agonist concentration in the ER some hundredfold lower than the extracellular concentrations that transiently activate α4β2 nAChRs (<xref ref-type="bibr" rid="bib29">Kuryatov et al., 2005</xref>).</p><p>Given these challenges, further progress may be possible now that we have two types of real-time, living cellular preparations. (1) For decades, cellular preparations have been available to measure nAChR pharmacodynamics and upregulation. (2) Now, the iDrugSnFRs present a paradigm to measure cellular and subcellular pharmacokinetics. The iDrugSnFR paradigm will be useful beyond the explicit case of nicotine addiction, with application to other exogenous neural drugs.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">BL21(DE3)</td><td align="left" valign="bottom">Agilent Technologies, Santa Clara, CA</td><td align="char" char="." valign="bottom">200131</td><td align="left" valign="bottom">Chemically competent</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HeLa</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-2;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0030">CVCL_0030</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Primary hippocampal neurons</td><td align="left" valign="bottom">Caltech animal facilities</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom">Freshly isolated from <italic>Mus musculus</italic></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">iAChSnFR</td><td align="left" valign="bottom">Loren Looger</td><td align="left" valign="bottom">Addgene: 137955</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">iDianiSnFR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177741<break/></td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">iCytSnFR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177738</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">iCyt_F_SnFR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177739</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">iCyt_BrEt_SnFR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177740</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iDianiSnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177751</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iDianiSnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177750</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iCytSnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177743</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iCytSnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177742</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iCyt_F_SnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177745</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iCyt_F_SnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177744</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iCyt_BrEt_SnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177747</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV(MinDis)-iCyt_BrEt_SnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177746</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iDianiSnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177759</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iDianiSnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177758</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iCytSnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177753</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iCytSnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177752</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iCyt_F_SnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177755</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iCyt_F_SnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177754</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iCyt_BrEt_SnFR_PM</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177757</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV9-hSyn-iCyt_BrEt_SnFR_ER</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene: 177756</td><td align="left" valign="bottom">Obtainable through Addgene</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Phusion High-Fidelity PCR Kit</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">E0553L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Q5 Site-Directed Mutagenesis Kit</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">E0554S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QIAprep Spin Miniprep Kit</td><td align="left" valign="bottom">QIAGEN SCR_008539</td><td align="char" char="." valign="bottom">27104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EndoFree Plasmid Maxi Kit</td><td align="left" valign="bottom">QIAGEN SCR_008539</td><td align="char" char="." valign="bottom">12362</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QIAquick PCR Purification Kit</td><td align="left" valign="bottom">QIAGEN SCR_008539</td><td align="char" char="." valign="bottom">28104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QIAquick Gel Extraction Kit</td><td align="left" valign="bottom">QIAGEN SCR_008539</td><td align="char" char="." valign="bottom">28704</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">AAVpro Purification Kit</td><td align="left" valign="bottom">Takara Bio Inc.</td><td align="char" char="." valign="bottom">6666</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PACT premier</td><td align="left" valign="bottom">Molecular Dimensions</td><td align="left" valign="bottom">MD1-29</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">10-Fluorocytisine</td><td align="left" valign="bottom">Tim Gallagher</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib45">Rego Campello et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">9-Bromo-10-ethylcytisine</td><td align="left" valign="bottom">Tim Gallagher</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib45">Rego Campello et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lipofectamine 2000 Transfection Reagent</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="char" char="." valign="bottom">11668027</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lipofectamine 3000 Transfection Reagent</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">L3000015</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Spartan’20</td><td align="left" valign="bottom">Wavefunction, Inc.</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014901">SCR_014901</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">NanoAnalyze</td><td align="left" valign="bottom">TA Instruments</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.tainstruments.com/sw/nano_analyze.html">https://www.tainstruments.com/sw/nano_analyze.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">OriginPro 2018</td><td align="left" valign="bottom">OriginLab</td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014212">:SCR_014212</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">KaleidaGraph</td><td align="left" valign="bottom">Synergy</td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014980">:SCR_014980</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">:SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">XDS Program Package</td><td align="left" valign="bottom">MPI for Medical Research, Heidelberg</td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015652">:SCR_015652</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Phenix</td><td align="left" valign="bottom">Phenix</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014224">SCR_014224</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016736">SCR_016736</ext-link></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Coot</td><td align="left" valign="bottom">MRC Laboratory of Molecular Biology</td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014222">:SCR_014222</ext-link></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib16">Emsley et al., 2010</xref></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Crystallography</title><p>The gene encoding the full-length biosensor iNicSnFR3a was previously cloned into a bacterial expression vector (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). To improve crystallization, we deleted the N-terminal HA tag and the N-terminal Myc tag, forming the constructs with the suffix ‘dt.’ These deletions were carried out with the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA). All proteins were overexpressed in <italic>E. coli</italic> BL21-gold (DE3) cells (Agilent Technologies, Santa Clara, CA) using ZYM-5052 autoinduction media (<xref ref-type="bibr" rid="bib54">Studier, 2005</xref>). Cells were collected by centrifugation and stored at –80°C until use.</p><p>For purification, frozen cell pellets were resuspended in lysis buffer containing 100 mM NaCl, 20 mM Tris, pH 7.5, 20 mM imidazole, pH 7.5, 5 mM β-mercaptoethanol (BME), lysozyme, DNase, and protease inhibitor tablet. The resuspended cells were lysed by freezing and thawing using liquid nitrogen and a room temperature water bath for three cycles. Intact cells and cell debris were removed by centrifugation at ~20,000 × <italic>g</italic> for 40 min at 4°C. The supernatant was collected and loaded onto a prewashed Ni NTA column with wash buffer at 4°C. Ni NTA wash buffer contained 100 mM NaCl, 20 mM Tris, pH 7.5, 30 mM imidazole, pH 7.5, and 5 mM BME. Elution was achieved using the same buffer with 300 mM imidazole, pH 7.5. The eluted sample was further purified by size-exclusion chromatography using HiLoad 16/60 Superdex 200 in the same buffer without imidazole and BME. Peak fractions were collected and concentrated to ~50 mg/ml with Amicon Ultra 15 filter unit (Millipore, Burlington, MA) with 10 kDa cutoff.</p><p>For all constructs, initial crystallization screening was carried out with 40 mg/ml protein in the presence and absence of 10 mM nicotine or varenicline. iNicSnFR3adt crystallized separately with 10 mM nicotine and varenicline in PACT premier (Molecular Dimensions, Sheffield, England), condition #96 with 0.2 M sodium malonate dibasic monohydrate, 0.1 M Bis-Tris Propane, pH 8.5, and 20% polyethylene glycol (PEG) 3350 at 20°C. Crystals of iNicSnFR3adt grew within 2 weeks of crystallization in a hexagonal rod shape with dimensions of ~80 μm × 80 μm × 300 μm. Crystals were harvested and cryo-protected in 25% ethylene glycol, 0.2 M sodium malonate dibasic monohydrate, 0.1 M Bis-Tris Propane pH 8.5, and 20% PEG 3350. Phase information was obtained through soaking with KI before cryo-protection. The unliganded iNicSnFR3adt crystallized in Morpheus (Molecular Dimensions), condition #92 with 2.5% PEG 1000, 12.5% PEG 3350, 12.5% 2-methyl-2,4-pentanediol, 0.02 M of each amino acid, and 0.1 M MOPS/HEPES-Na, pH 7.5 at 23°C with no further optimization.</p><p>X-ray datasets were collected at Stanford Synchrotron Radiation Laboratory beamline 12-2 and Advanced Light Source beamline 5.0.2 using Pilatus 6M detectors. All datasets were processed and integrated with XDS (<xref ref-type="bibr" rid="bib26">Kabsch, 2010</xref>) and scaled with Aimless (<xref ref-type="bibr" rid="bib59">Winn et al., 2011</xref>). For iNicSnFR3adt, molecular replacement was carried out using domains of the unliganded structure (PDB ID 6EFR) with Phaser in Phenix (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>). The experimental phase information of KI-soaked crystals of iNicSnFR3adt was obtained with MR-SAD using AutoSol in Phenix (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>). Molecular replacements of the remaining structures were carried out with the refined model of iNicSnFR3adt. Iterative refinement and model building cycles for all structures were carried out separately with phenix.refine in Phenix (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>) and Coot (<xref ref-type="bibr" rid="bib16">Emsley et al., 2010</xref>).</p></sec><sec id="s4-2"><title>Directed evolution of iDrugSnFR proteins using bacterial-expressed protein assays</title><p>Starting with iAChSnFR and intermediate biosensor constructs of that sensor, we constructed and optimized iDrugSnFRs for each drug partner during iterative rounds of SSM as previously described (<xref ref-type="bibr" rid="bib4">Bera et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). We utilized the 22-codon procedure including a mixture of three primers, creating 22 unique codons encoding the 20 canonical amino acids (<xref ref-type="bibr" rid="bib27">Kille et al., 2013</xref>). The 22-codon procedure yields an estimated &gt;96% residue coverage for a collection of 96 randomly chosen clones.</p><p>A Tecan Spark M10 96-well fluorescence plate reader (Tecan, Männedorf, Switzerland) was used to measure baseline and drug-induced fluorescence (F<sub>0</sub> and ΔF, respectively). Bacterial lysates were tested with excitation at 485 nm and emission at 535 nm. Lysates were also measured against choline to evaluate potential endogenous intracellular binding. Promising clones were amplified and sequenced. The optimally responding construct in each round of SSM was used as a template for the next round of SSM.</p><p>S-slope allows for comparison between iDrugSnFRs with differing ΔF<sub>max</sub>/F<sub>0</sub> values (<xref ref-type="bibr" rid="bib4">Bera et al., 2019</xref>) at the beginning of the dose–response relation, which is usually the pharmacologically relevant range. With lysates or purified protein, which allow complete dose–response relations, the Hill coefficient is near 1.0. We therefore calculated<disp-formula id="equ1">,<mml:math id="m1"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfrac><mml:mrow><mml:mi>Δ</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>in units of µM<sup>–1</sup>.</p></sec><sec id="s4-3"><title>Measurements of purified iDrugSnFRs</title><p>Biosensors selected for further study were purified using a His<sub>6</sub> sequence using an ÄKTA Start FPLC (GE Healthcare, Chicago, IL) as previously described (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). Performance of protein quantification and dose–response relations for drug–sensor partners was also as previously described (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). Where appropriate, we corrected for depletion of the ligand by binding with the equation,<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>−</mml:mo><mml:msqrt><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>s</mml:mi><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>L</mml:mi><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>D</mml:mi></mml:msub></mml:msqrt><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>D</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where K<sub>D</sub> is the ligand–sensor equilibrium dissociation constant (we assume that K<sub>D</sub> = EC<sub>50</sub>), [S] is the iDrugSnFR protein concentration (typically 100 nM), and [L] is the nominal ligand concentration.</p></sec><sec id="s4-4"><title>Isothermal titration calorimetry</title><p>Experiments were performed on an Affinity ITC (TA instruments, New Castle, DE) at 25°C. The iDrugSnFR protein was buffer-exchanged into 3× PBS, pH 7.0. The nicotinic agonists were dissolved in the same buffer. 800 µM cytisine (Sigma-Aldrich, Munich, Germany) was titrated into 80 µM iCytSnFR, 160 µM 10-fluorocytisine was titrated into 16 µM iCyt_F_SnFR. 470 µM 9-bromo-10-ethylcytisine was titrated into 47 µM iCyt_BrEt_SnFR. 1.5 mM dianicline (Tocris, Bio-Techne, Minneapolis, MN) was titrated into 150 µM iDianiSnFR. Analysis, including correction for changes in enthalpy generated from the dilution of the ligands, was performed using a single-site binding model in the manufacturer’s NanoAnalyze software.</p></sec><sec id="s4-5"><title>Stopped-flow kinetic analysis</title><p>Kinetics were determined by mixing equal volumes of 0.2 µM iDrugSnFR protein (in 3× PBS, pH 7.0) with varying concentrations of cognate ligand in an Applied Photophysics (Surrey, UK) SX20 stopped-flow fluorimeter with 490 nm LED excitation and 510 nm long-pass filter at room temperature (22°C). ‘Mixing shots’ were repeated five times and averaged (except for 100 s experiments, which were collected only once). Standard deviations are not included on the plots, but are nearly the same size as the data markers. The first 3 ms of data were ignored because of mixing artifacts and account for the dead time of the instrument.</p><p>Data were plotted and time courses were fitted, when possible, to a single exponential, and k<sub>obs</sub> was plotted as a function of [ligand]. The linear portion of that graph was fit, with the slope reporting k<sub>1</sub> and the y-intercept reporting k<sub>-1</sub>. When the time course did not fit well to a single rising exponential, it was fitted to the sum of two increasing exponentials, and the first rise (k<sub>obs1</sub>) was treated as above to determine k<sub>1</sub> and k<sub>-1</sub>.</p></sec><sec id="s4-6"><title>Expression in mammalian cells</title><p>We constructed two variants of each iDrugSnFR for expression in mammalian cells. The PM (suffix _PM) and ER (suffix _ER) variants were constructed by circular polymerase extension cloning (<xref ref-type="bibr" rid="bib44">Quan and Tian, 2009</xref>). To create the _PM constructs, we cloned the bacterial constructs into pCMV(MinDis), a variant of pDisplay (Thermo Fisher Scientific, Waltham, MA) lacking the hemagglutinin tag (<xref ref-type="bibr" rid="bib34">Marvin et al., 2013</xref>). To generate the _ER constructs, we replaced the 14 C-terminal amino acids (QVDEQKLISEEDLN, including the Myc tag) with an ER retention motif, QTAEKDEL (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>).</p><p>We transfected the iDrugSnFR cDNA constructs into HeLa and HEK293T cells. Cell lines were purchased from ATCC (Manassas, VA) and cultured according to ATCC protocols. We purchased new aliquots of the cell lines listed above at 6-month intervals to ensure reproducibility. Mycoplasma contamination was assayed at 6-month intervals and was negative over the course of these experiments. For chemical transfection, we utilized either Lipofectamine 2000 or Lipofectamine 3000 (Thermo Fisher Scientific) following the manufacturer’s recommended protocol. Cells were incubated in the transfection medium for 24 hr and imaged 24–48 hr after transfection.</p></sec><sec id="s4-7"><title>Millisecond timescale microperfusion</title><p>HEK293T cells were imaged using a Nikon (Tokyo, Japan) DIAPHOT 300 with a Zeiss ×63 objective (1.5 NA). Because the ligand concentration after micro-iontophoretic drug application (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>) is unknown, we applied drugs with a laminar-flow microperfusion (model SS-77B Fast-Step perfusion system; Warner Instruments, Holliston, MA). In an array of three square glass capillaries (600 µ i.d.), the center capillary contained vehicle (Hanks buffered salt solution [HBSS]) plus drug, while the two outer capillaries contained vehicle only. Vehicle also flowed from a separate input connected to the bath perfusion system. Solution exchange, measured by loading the center capillary with dye, had a time constant of 90 ± 20 ms (n = 6 trials).</p><p>We used Fiji ImageJ and Origin Pro 2018 (OriginLab, Northampton, MA) to fit the rise and decay of the iCytSnFR_PM drug response to the sum of one or two exponential components. An F-test determined whether two exponential components fit the data significantly better than 1 (p&lt;0.05). Statistical comparisons between groups were carried out using ANOVA.</p></sec><sec id="s4-8"><title>AAV production and transduction in primary mouse hippocampal neuronal culture</title><p>The adeno-associated virus plasmid vector AAV9-hSyn was described previously (<xref ref-type="bibr" rid="bib9">Challis et al., 2019</xref>). Virus was purified using the AAVpro Purification Kit (TakaraBio USA). Mouse embryo dissection and culture were previously described (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>). About 4 days after dissection, we transduced the _ER construct at an MOI of 0.5–5 × 10<sup>4</sup>; and separately, the _PM construct was transduced at an MOI of 0.5–1 × 10<sup>5</sup>. Neurons were imaged ~2–3 weeks post-transduction.</p></sec><sec id="s4-9"><title>Time-resolved fluorescence measurements in live mammalian cells and primary mouse hippocampal neuronal culture</title><p>Time-resolved dose–response imaging was performed on a modified Olympus IX-81 microscope (Olympus Microscopes, Tokyo, Japan), in widefield epifluorescence mode using a ×40 lens. Images were acquired at 2–4 frames/s with a back-illuminated EMCCD camera (iXon DU-897, Andor Technology USA, South Windsor, CT), controlled by Andor IQ3 software. Fluorescence measurements at λ<sub>ex</sub> = 470 nm and the epifluorescence cube were as previously described (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Srinivasan et al., 2011</xref>).</p><p>Solutions were delivered from elevated reservoirs by gravity flow, via solenoid valves (Automate Scientific, Berkeley, CA), then through tubing fed into a manifold, at a rate of 1–2 ml/min. The vehicle was HBSS. Other details have been described (<xref ref-type="bibr" rid="bib51">Shivange et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Srinivasan et al., 2011</xref>). Data analysis procedures included subtraction of ‘blank’ (extracellular) areas and corrections for baseline drifts using Origin Pro 2018.</p></sec><sec id="s4-10"><title>Spinning disk confocal fluorescence images</title><p>HeLa cells and mouse primary hippocampal culture were transfected or transduced as described above. Live-cell images were collected using a Nikon Ti-E spinning disk laser scanning confocal inverted microscope equipped with ×100 objective, 1.49 NA (oil), 120 μm WD. The laser wavelength was 488 nm at 15% power. Dishes were imaged in a custom incubator (Okolab, Ottaviano, Italy) at 37°C and 5% CO<sub>2</sub>. Initial images were taken in HBSS. To add drug, we doubled the bath volume by adding HBSS containing drug using a hand-held pipette. The final drug concentrations were dianicline, 15 µM; cytisine, 10 µM; 10-fluorocytisine, 10 µM; and 9-bromo-10-ethylcytisine, 7.5 µM.</p></sec><sec id="s4-11"><title>LogD calculations</title><p>We used Chemicalize (<ext-link ext-link-type="uri" xlink:href="https://chemaxon.com/products/chemicalize">https://chemaxon.com/products/chemicalize</ext-link>). The software uses algorithms to calculate logP and pK<sub>a</sub>. The software then calculates</p><p>LogD<sub>pH7.4</sub> = logP -log[1 + 10<sup>7.4 - pKa</sup>].</p></sec><sec id="s4-12"><title>Plasmid availability</title><p>We will deposit plasmids with the following cDNAs at Addgene:</p><list list-type="bullet"><list-item><p>iDianiSnFR</p></list-item><list-item><p>iCytSnFR</p></list-item><list-item><p>iCyt_F_SnFR</p></list-item><list-item><p>iCyt_BrEt_SnFR</p></list-item></list><p>We will deposit the following plasmids at Addgene:</p><list list-type="bullet"><list-item><p>pCMV(MinDis)-iDianiSnFR_PM</p></list-item><list-item><p>pCMV(MinDis)-iCytSnFR_PM</p></list-item><list-item><p>pCMV(MinDis)-iCyt_F_SnFR_PM</p></list-item><list-item><p>pCMV(MinDis)-iCyt_BrEt_SnFR_PM</p></list-item><list-item><p>pCMV(MinDis)-iDianiSnFR_ER</p></list-item><list-item><p>pCMV(MinDis)-iCytSnFR_ER</p></list-item><list-item><p>pCMV(MinDis)-iCyt_F_SnFR_ER</p></list-item><list-item><p>pCMV(MinDis)-iCyt_BrEt_SnFR_ER</p></list-item><list-item><p>pAAV9-hSyn-iDianiSnFR_PM</p></list-item><list-item><p>pAAV9-hSyn-iCytSnFR_PM</p></list-item><list-item><p>pAAV9-hSyn-iCyt_F_SnFR_PM</p></list-item><list-item><p>pAAV9-hSyn iCyt_BrEt_SnFR_PM</p></list-item><list-item><p>pAAV9-hSyn-iDianiSnFR_ER</p></list-item><list-item><p>pAAV9-hSyn-iCytSnFR_ER</p></list-item><list-item><p>pAAV9-hSyn-iCyt_F_SnFR_ER</p></list-item><list-item><p>pAAV9-hSyn iCyt_BrEt_SnFR_ER</p></list-item></list></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Investigation</p></fn><fn fn-type="con" id="con9"><p>Data curation, Investigation, Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Visualization</p></fn><fn fn-type="con" id="con11"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Data curation, Resources, Validation</p></fn><fn fn-type="con" id="con14"><p>Investigation, Methodology, Resources</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Data curation, Funding acquisition, Project administration, Resources, Supervision</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Data curation, Funding acquisition, Project administration, Supervision, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Software, Supervision, Visualization, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Generation of primary mouse hippocampal culture was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to the approved institutional animal care and use committee (IACUC) protocols (IA19-1386) of California Institute of Technology. Dissections were performed after euthanasia of the pregnant mouse and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Data collection and refinement statistics of iNicSnFR 3a.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74648-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Stopped-flow model determined rate constants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74648-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-74648-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The plasmids and associated database entries are available from Addgene (as named in our manuscript) with genetic maps. The Protein Data Bank has published the crystallographics and structural data (accession codes 7S7T, 7S7U, 7S7V). Supplementary File 1 gives relevant details.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Shivange</surname><given-names>AV</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Rees</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>iNicSnFR3a Nicotine Sensor comprising Periplasmic Binding sequence plus Fluorescent Sequence with varenicline bound</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7S7T">7S7T</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Shivange</surname><given-names>AV</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Rees</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Crystal structure of iNicSnFR3a Fluorescent Nicotine Sensor with nicotine bound</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7S7U">7S7U</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Shivange</surname><given-names>AV</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Rees</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Crystal structure of iNicSnFR3a Fluorescent Nicotine Sensor</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7S7V">7S7V</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Stefan Petrovic for his stewardship of the isothermal titration calorimeter in the Caltech Center for Molecular Medicine, Jens Kaiser for help with structural studies at the Caltech Molecular Observatory, the Gradinaru lab and Caltech CLOVER Center for help with viral vectors, and Andres Collazo and Giada Spigolon at the Caltech Biological Imaging Facility. We thank Zoe Beatty, Kallol Bera, Eve Fine, Shan Huang, Elaine Lin, Stephen Mayo, Lin Tian, and Elizabeth Unger for advice and guidance. We thank Achieve Life Sciences for a gift of cytisine. California Tobacco-Related Disease Research Program (TRDRP) (27 FT-0022), ALN. California Tobacco-Related Disease Research Program (TRDRP) (27IP-0057), HAL. California Tobacco-Related Disease Research Program (TRDRP) (T29IR0455), DAD. NIH (GM-123582, DA043829), HAL. NIH (DA049140, GM7616), AKM. Howard Hughes Medical Institute (LLL, JSM, DCR). UK Engineering and Physical Sciences Research Council (no. EP/N024117/1), TG. Leiden University International Studies Fund (LISF L18020-1-45), LL.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>L-W</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>R</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astroug</surname><given-names>H</given-names></name><name><surname>Simeonova</surname><given-names>R</given-names></name><name><surname>Kassabova</surname><given-names>LV</given-names></name><name><surname>Danchev</surname><given-names>N</given-names></name><name><surname>Svinarov</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits</article-title><source>Interdisciplinary Toxicology</source><volume>3</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2478/v10102-010-0003-5</pub-id><pub-id pub-id-type="pmid">21217866</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>LM</given-names></name><name><surname>Hughes</surname><given-names>TE</given-names></name><name><surname>Drobizhev</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Deciphering the molecular mechanism responsible for GCaMP6m’s Ca2+-dependent change in fluorescence</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0170934</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0170934</pub-id><pub-id pub-id-type="pmid">28182677</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bera</surname><given-names>K</given-names></name><name><surname>Kamajaya</surname><given-names>A</given-names></name><name><surname>Shivange</surname><given-names>AV</given-names></name><name><surname>Muthusamy</surname><given-names>AK</given-names></name><name><surname>Nichols</surname><given-names>AL</given-names></name><name><surname>Borden</surname><given-names>PM</given-names></name><name><surname>Grant</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Bishara</surname><given-names>I</given-names></name><name><surname>Chin</surname><given-names>TM</given-names></name><name><surname>Cohen</surname><given-names>BN</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Unger</surname><given-names>EK</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Marvin</surname><given-names>JS</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum</article-title><source>Frontiers in Cellular Neuroscience</source><volume>13</volume><elocation-id>499</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2019.00499</pub-id><pub-id pub-id-type="pmid">31798415</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blom</surname><given-names>AEM</given-names></name><name><surname>Campello</surname><given-names>HR</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Gallagher</surname><given-names>T</given-names></name><name><surname>Dougherty</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Probing Binding Interactions of Cytisine Derivatives to the α4β2 Nicotinic Acetylcholine Receptor</article-title><source>Journal of the American Chemical Society</source><volume>141</volume><fpage>15840</fpage><lpage>15849</lpage><pub-id pub-id-type="doi">10.1021/jacs.9b06580</pub-id><pub-id pub-id-type="pmid">31518499</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Borden</surname><given-names>P</given-names></name><name><surname>Shivange</surname><given-names>AV</given-names></name><name><surname>Marvin</surname><given-names>JS</given-names></name><name><surname>Cichon</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>C</given-names></name><name><surname>Podgorski</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Genetically Encoded Fluorescent Sensor for in Vivo Acetylcholine Detection</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.02.07.939504</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brejc</surname><given-names>K</given-names></name><name><surname>Sixma</surname><given-names>TK</given-names></name><name><surname>Kitts</surname><given-names>PA</given-names></name><name><surname>Kain</surname><given-names>SR</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name><name><surname>Ormö</surname><given-names>M</given-names></name><name><surname>Remington</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Structural basis for dual excitation and photoisomerization of the Aequorea victoria green fluorescent protein</article-title><source>PNAS</source><volume>94</volume><fpage>2306</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.6.2306</pub-id><pub-id pub-id-type="pmid">9122190</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celie</surname><given-names>PHN</given-names></name><name><surname>van Rossum-Fikkert</surname><given-names>SE</given-names></name><name><surname>van Dijk</surname><given-names>WJ</given-names></name><name><surname>Brejc</surname><given-names>K</given-names></name><name><surname>Smit</surname><given-names>AB</given-names></name><name><surname>Sixma</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures</article-title><source>Neuron</source><volume>41</volume><fpage>907</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(04)00115-1</pub-id><pub-id pub-id-type="pmid">15046723</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Challis</surname><given-names>RC</given-names></name><name><surname>Kumar</surname><given-names>SR</given-names></name><name><surname>Chan</surname><given-names>KY</given-names></name><name><surname>Challis</surname><given-names>C</given-names></name><name><surname>Beadle</surname><given-names>K</given-names></name><name><surname>Jang</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Rajendran</surname><given-names>PS</given-names></name><name><surname>Tompkins</surname><given-names>JD</given-names></name><name><surname>Shivkumar</surname><given-names>K</given-names></name><name><surname>Deverman</surname><given-names>BE</given-names></name><name><surname>Gradinaru</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Publisher Correction: Systemic AAV vectors for widespread and targeted gene delivery in rodents</article-title><source>Nature Protocols</source><volume>14</volume><elocation-id>2597</elocation-id><pub-id pub-id-type="doi">10.1038/s41596-019-0155-5</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chellappan</surname><given-names>SK</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Tueckmantel</surname><given-names>W</given-names></name><name><surname>Kellar</surname><given-names>KJ</given-names></name><name><surname>Kozikowski</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity</article-title><source>Journal of Medicinal Chemistry</source><volume>49</volume><fpage>2673</fpage><lpage>2676</lpage><pub-id pub-id-type="doi">10.1021/jm051196m</pub-id><pub-id pub-id-type="pmid">16640326</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coe</surname><given-names>JW</given-names></name><name><surname>Brooks</surname><given-names>PR</given-names></name><name><surname>Vetelino</surname><given-names>MG</given-names></name><name><surname>Wirtz</surname><given-names>MC</given-names></name><name><surname>Arnold</surname><given-names>EP</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Sands</surname><given-names>SB</given-names></name><name><surname>Davis</surname><given-names>TI</given-names></name><name><surname>Lebel</surname><given-names>LA</given-names></name><name><surname>Fox</surname><given-names>CB</given-names></name><name><surname>Shrikhande</surname><given-names>A</given-names></name><name><surname>Heym</surname><given-names>JH</given-names></name><name><surname>Schaeffer</surname><given-names>E</given-names></name><name><surname>Rollema</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Mansbach</surname><given-names>RS</given-names></name><name><surname>Chambers</surname><given-names>LK</given-names></name><name><surname>Rovetti</surname><given-names>CC</given-names></name><name><surname>Schulz</surname><given-names>DW</given-names></name><name><surname>Tingley</surname><given-names>FD</given-names></name><name><surname>O’Neill</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation</article-title><source>Journal of Medicinal Chemistry</source><volume>48</volume><fpage>3474</fpage><lpage>3477</lpage><pub-id pub-id-type="doi">10.1021/jm050069n</pub-id><pub-id pub-id-type="pmid">15887955</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Bergis</surname><given-names>OE</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Lochead</surname><given-names>AW</given-names></name><name><surname>Jegham</surname><given-names>S</given-names></name><name><surname>Biton</surname><given-names>B</given-names></name><name><surname>Leonardon</surname><given-names>J</given-names></name><name><surname>Avenet</surname><given-names>P</given-names></name><name><surname>Sgard</surname><given-names>F</given-names></name><name><surname>Besnard</surname><given-names>F</given-names></name><name><surname>Graham</surname><given-names>D</given-names></name><name><surname>Coste</surname><given-names>A</given-names></name><name><surname>Oblin</surname><given-names>A</given-names></name><name><surname>Curet</surname><given-names>O</given-names></name><name><surname>Voltz</surname><given-names>C</given-names></name><name><surname>Gardes</surname><given-names>A</given-names></name><name><surname>Caille</surname><given-names>D</given-names></name><name><surname>Perrault</surname><given-names>G</given-names></name><name><surname>George</surname><given-names>P</given-names></name><name><surname>Soubrie</surname><given-names>P</given-names></name><name><surname>Scatton</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>306</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.049262</pub-id><pub-id pub-id-type="pmid">12682217</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Boer</surname><given-names>M</given-names></name><name><surname>Gouridis</surname><given-names>G</given-names></name><name><surname>Muthahari</surname><given-names>YA</given-names></name><name><surname>Cordes</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-Molecule Observation of Ligand Binding and Conformational Changes in FeuA</article-title><source>Biophysical Journal</source><volume>117</volume><fpage>1642</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2019.08.005</pub-id><pub-id pub-id-type="pmid">31537314</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempsey</surname><given-names>D</given-names></name><name><surname>Tutka</surname><given-names>P</given-names></name><name><surname>Jacob</surname><given-names>P</given-names></name><name><surname>Allen</surname><given-names>F</given-names></name><name><surname>Schoedel</surname><given-names>K</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity</article-title><source>Clinical Pharmacology and Therapeutics</source><volume>76</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2004.02.011</pub-id><pub-id pub-id-type="pmid">15229465</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmore</surname><given-names>DE</given-names></name><name><surname>Dougherty</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A computational study of nicotine conformations in the gas phase and in water</article-title><source>The Journal of Organic Chemistry</source><volume>65</volume><fpage>742</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1021/jo991383q</pub-id><pub-id pub-id-type="pmid">10814006</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of Coot</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagerstrom</surname><given-names>K</given-names></name><name><surname>Balfour</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Neuropharmacology and potential efficacy of new treatments for tobacco dependence</article-title><source>Expert Opinion on Investigational Drugs</source><volume>15</volume><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1517/13543784.15.2.107</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>Structure, Function, and Application of Bacterial ABC Transporters</source><publisher-name>California Institute of Technology</publisher-name></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouridis</surname><given-names>G</given-names></name><name><surname>Schuurman-Wolters</surname><given-names>GK</given-names></name><name><surname>Ploetz</surname><given-names>E</given-names></name><name><surname>Husada</surname><given-names>F</given-names></name><name><surname>Vietrov</surname><given-names>R</given-names></name><name><surname>Boer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Conformational dynamics in substrate-binding domains influences transport in the ABC importer GlnPQ</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>22</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2929</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govind</surname><given-names>AP</given-names></name><name><surname>Vallejo</surname><given-names>YF</given-names></name><name><surname>Stolz</surname><given-names>JR</given-names></name><name><surname>Yan</surname><given-names>JZ</given-names></name><name><surname>Swanson</surname><given-names>GT</given-names></name><name><surname>Green</surname><given-names>WN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Selective and regulated trapping of nicotinic receptor weak base ligands and relevance to smoking cessation</article-title><source>eLife</source><volume>6</volume><elocation-id>e25651</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.25651</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>K</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Asada</surname><given-names>H</given-names></name><name><surname>Yurugi-Kobayashi</surname><given-names>T</given-names></name><name><surname>Shiroishi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name><name><surname>Haga</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist</article-title><source>Nature</source><volume>482</volume><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nature10753</pub-id><pub-id pub-id-type="pmid">22278061</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>BJ</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inside-out neuropharmacology of nicotinic drugs</article-title><source>Neuropharmacology</source><volume>96</volume><fpage>178</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.01.022</pub-id><pub-id pub-id-type="pmid">25660637</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houllier</surname><given-names>N</given-names></name><name><surname>Gouault</surname><given-names>S</given-names></name><name><surname>Lasne</surname><given-names>MC</given-names></name><name><surname>Rouden</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regio- and diastereoselective functionalization of (−)-cytisine</article-title><source>Tetrahedron</source><volume>62</volume><fpage>11679</fpage><lpage>11686</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2006.09.057</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imming</surname><given-names>P</given-names></name><name><surname>Klaperski</surname><given-names>P</given-names></name><name><surname>Stubbs</surname><given-names>MT</given-names></name><name><surname>Seitz</surname><given-names>G</given-names></name><name><surname>Gündisch</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Syntheses and evaluation of halogenated cytisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands</article-title><source>European Journal of Medicinal Chemistry</source><volume>36</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/s0223-5234(01)01222-3</pub-id><pub-id pub-id-type="pmid">11461763</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>SH</given-names></name><name><surname>Sheridan</surname><given-names>J</given-names></name><name><surname>Newcombe</surname><given-names>D</given-names></name><name><surname>Tingle</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Plasma concentrations of cytisine, a commercially available plant-based alkaloid, in healthy adult smokers taking recommended doses for smoking cessation</article-title><source>Xenobiotica; the Fate of Foreign Compounds in Biological Systems</source><volume>48</volume><fpage>1245</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1080/00498254.2017.1409916</pub-id><pub-id pub-id-type="pmid">29168931</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kille</surname><given-names>S</given-names></name><name><surname>Acevedo-Rocha</surname><given-names>CG</given-names></name><name><surname>Parra</surname><given-names>LP</given-names></name><name><surname>Zhang</surname><given-names>Z-G</given-names></name><name><surname>Opperman</surname><given-names>DJ</given-names></name><name><surname>Reetz</surname><given-names>MT</given-names></name><name><surname>Acevedo</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Reducing codon redundancy and screening effort of combinatorial protein libraries created by saturation mutagenesis</article-title><source>ACS Synthetic Biology</source><volume>2</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1021/sb300037w</pub-id><pub-id pub-id-type="pmid">23656371</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozikowski</surname><given-names>AP</given-names></name><name><surname>Chellappan</surname><given-names>SK</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Bajjuri</surname><given-names>KM</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Kellar</surname><given-names>KJ</given-names></name><name><surname>Petukhov</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chemical medicine: novel 10-substituted cytisine derivatives with increased selectivity for alpha4beta2 nicotinic acetylcholine receptors</article-title><source>ChemMedChem</source><volume>2</volume><fpage>1157</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1002/cmdc.200700073</pub-id><pub-id pub-id-type="pmid">17530728</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuryatov</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Lindstrom</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors</article-title><source>Molecular Pharmacology</source><volume>68</volume><fpage>1839</fpage><lpage>1851</lpage><pub-id pub-id-type="doi">10.1124/mol.105.012419</pub-id><pub-id pub-id-type="pmid">16183856</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancet</surname><given-names>D</given-names></name><name><surname>Pecht</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Kinetic evidence for hapten-induced conformational transition in immunoglobin MOPC 460</article-title><source>PNAS</source><volume>73</volume><fpage>3549</fpage><lpage>3553</lpage><pub-id pub-id-type="doi">10.1073/pnas.73.10.3549</pub-id><pub-id pub-id-type="pmid">1068466</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Houezec</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review</article-title><source>The International Journal of Tuberculosis and Lung Disease</source><volume>7</volume><fpage>811</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">12971663</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnus</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Bonaventura</surname><given-names>J</given-names></name><name><surname>Zemla</surname><given-names>R</given-names></name><name><surname>Gomez</surname><given-names>JL</given-names></name><name><surname>Ramirez</surname><given-names>MH</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Galvan</surname><given-names>A</given-names></name><name><surname>Basu</surname><given-names>J</given-names></name><name><surname>Michaelides</surname><given-names>M</given-names></name><name><surname>Sternson</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ultrapotent chemogenetics for research and potential clinical applications</article-title><source>Science</source><volume>364</volume><elocation-id>eaav5282</elocation-id><pub-id pub-id-type="doi">10.1126/science.aav5282</pub-id><pub-id pub-id-type="pmid">30872534</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcaurelle</surname><given-names>LA</given-names></name><name><surname>Johannes</surname><given-names>C</given-names></name><name><surname>Yohannes</surname><given-names>D</given-names></name><name><surname>Tillotson</surname><given-names>BP</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>19</volume><fpage>2500</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2009.03.037</pub-id><pub-id pub-id-type="pmid">19329314</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marvin</surname><given-names>JS</given-names></name><name><surname>Borghuis</surname><given-names>BG</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Cichon</surname><given-names>J</given-names></name><name><surname>Harnett</surname><given-names>MT</given-names></name><name><surname>Akerboom</surname><given-names>J</given-names></name><name><surname>Gordus</surname><given-names>A</given-names></name><name><surname>Renninger</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>T-W</given-names></name><name><surname>Bargmann</surname><given-names>CI</given-names></name><name><surname>Orger</surname><given-names>MB</given-names></name><name><surname>Schreiter</surname><given-names>ER</given-names></name><name><surname>Demb</surname><given-names>JB</given-names></name><name><surname>Gan</surname><given-names>W-B</given-names></name><name><surname>Hires</surname><given-names>SA</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An optimized fluorescent probe for visualizing glutamate neurotransmission</article-title><source>Nature Methods</source><volume>10</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2333</pub-id><pub-id pub-id-type="pmid">23314171</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marvin</surname><given-names>JS</given-names></name><name><surname>Scholl</surname><given-names>B</given-names></name><name><surname>Wilson</surname><given-names>DE</given-names></name><name><surname>Podgorski</surname><given-names>K</given-names></name><name><surname>Kazemipour</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>JA</given-names></name><name><surname>Schoch</surname><given-names>S</given-names></name><name><surname>Quiroz</surname><given-names>FJU</given-names></name><name><surname>Rebola</surname><given-names>N</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Little</surname><given-names>JP</given-names></name><name><surname>Tkachuk</surname><given-names>AN</given-names></name><name><surname>Cai</surname><given-names>E</given-names></name><name><surname>Hantman</surname><given-names>AW</given-names></name><name><surname>Wang</surname><given-names>SS-H</given-names></name><name><surname>DePiero</surname><given-names>VJ</given-names></name><name><surname>Borghuis</surname><given-names>BG</given-names></name><name><surname>Chapman</surname><given-names>ER</given-names></name><name><surname>Dietrich</surname><given-names>D</given-names></name><name><surname>DiGregorio</surname><given-names>DA</given-names></name><name><surname>Fitzpatrick</surname><given-names>D</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Stability, affinity, and chromatic variants of the glutamate sensor iGluSnFR</article-title><source>Nature Methods</source><volume>15</volume><fpage>936</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1038/s41592-018-0171-3</pub-id><pub-id pub-id-type="pmid">30377363</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EJ</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Spurden</surname><given-names>D</given-names></name><name><surname>Ebbert</surname><given-names>JO</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis</article-title><source>Harm Reduction Journal</source><volume>6</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/1477-7517-6-25</pub-id><pub-id pub-id-type="pmid">19761618</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-Perez</surname><given-names>CL</given-names></name><name><surname>Noviello</surname><given-names>CM</given-names></name><name><surname>Hibbs</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>X-ray structure of the human α4β2 nicotinic receptor</article-title><source>Nature</source><volume>538</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1038/nature19785</pub-id><pub-id pub-id-type="pmid">27698419</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Kramer</surname><given-names>L</given-names></name><name><surname>Campbell</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure- and mechanism-guided design of single fluorescent protein-based biosensors</article-title><source>Nature Chemical Biology</source><volume>17</volume><fpage>509</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-00718-x</pub-id><pub-id pub-id-type="pmid">33558715</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>PT</given-names></name><name><surname>Lai</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Kaiser</surname><given-names>JT</given-names></name><name><surname>Rees</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Noncanonical role for the binding protein in substrate uptake by the MetNI methionine ATP Binding Cassette (ABC) transporter</article-title><source>PNAS</source><volume>115</volume><fpage>E10596</fpage><lpage>E10604</lpage><pub-id pub-id-type="doi">10.1073/pnas.1811003115</pub-id><pub-id pub-id-type="pmid">30352853</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormö</surname><given-names>M</given-names></name><name><surname>Cubitt</surname><given-names>AB</given-names></name><name><surname>Kallio</surname><given-names>K</given-names></name><name><surname>Gross</surname><given-names>LA</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name><name><surname>Remington</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Crystal structure of the Aequorea victoria green fluorescent protein</article-title><source>Science</source><volume>273</volume><fpage>1392</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1126/science.273.5280.1392</pub-id><pub-id pub-id-type="pmid">8703075</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipova</surname><given-names>I</given-names></name><name><surname>Stavrakov</surname><given-names>G</given-names></name><name><surname>Vassilev</surname><given-names>N</given-names></name><name><surname>Nikolova</surname><given-names>R</given-names></name><name><surname>Shivachev</surname><given-names>B</given-names></name><name><surname>Dimitrov</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cytisine as a scaffold for ortho-diphenylphosphinobenzenecarboxamide ligands for Pd-catalyzed asymmetric allylic alkylation</article-title><source>Journal of Organometallic Chemistry</source><volume>778</volume><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.jorganchem.2014.12.001</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieńko</surname><given-names>T</given-names></name><name><surname>Grudzień</surname><given-names>M</given-names></name><name><surname>Taciak</surname><given-names>PP</given-names></name><name><surname>Mazurek</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cytisine basicity, solvation, logP, and logD theoretical determination as tool for bioavailability prediction</article-title><source>Journal of Molecular Graphics &amp; Modelling</source><volume>63</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jmgm.2015.11.003</pub-id><pub-id pub-id-type="pmid">26609940</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Post</surname><given-names>MR</given-names></name><name><surname>Tender</surname><given-names>GS</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Dougherty</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Secondary Ammonium Agonists Make Dual Cation-π Interactions in α4β2 Nicotinic Receptors</article-title><source>ENeuro</source><volume>4</volume><elocation-id>ENEURO.0032-17.2017</elocation-id><pub-id pub-id-type="doi">10.1523/ENEURO.0032-17.2017</pub-id><pub-id pub-id-type="pmid">28589175</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Circular polymerase extension cloning of complex gene libraries and pathways</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6441</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006441</pub-id><pub-id pub-id-type="pmid">19649325</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rego Campello</surname><given-names>H</given-names></name><name><surname>Del Villar</surname><given-names>SG</given-names></name><name><surname>Honraedt</surname><given-names>A</given-names></name><name><surname>Minguez</surname><given-names>T</given-names></name><name><surname>Oliveira</surname><given-names>ASF</given-names></name><name><surname>Ranaghan</surname><given-names>KE</given-names></name><name><surname>Shoemark</surname><given-names>DK</given-names></name><name><surname>Bermudez</surname><given-names>I</given-names></name><name><surname>Gotti</surname><given-names>C</given-names></name><name><surname>Sessions</surname><given-names>RB</given-names></name><name><surname>Mulholland</surname><given-names>AJ</given-names></name><name><surname>Wonnacott</surname><given-names>S</given-names></name><name><surname>Gallagher</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine</article-title><source>Chem</source><volume>4</volume><fpage>1710</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1016/j.chempr.2018.05.007</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollema</surname><given-names>H</given-names></name><name><surname>Shrikhande</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>KM</given-names></name><name><surname>Tingley</surname><given-names>FD</given-names></name><name><surname>Coe</surname><given-names>JW</given-names></name><name><surname>O’Neill</surname><given-names>BT</given-names></name><name><surname>Tseng</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>EQ</given-names></name><name><surname>Mather</surname><given-names>RJ</given-names></name><name><surname>Hurst</surname><given-names>RS</given-names></name><name><surname>Williams</surname><given-names>KE</given-names></name><name><surname>de Vries</surname><given-names>M</given-names></name><name><surname>Cremers</surname><given-names>T</given-names></name><name><surname>Bertrand</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence</article-title><source>British Journal of Pharmacology</source><volume>160</volume><fpage>334</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00682.x</pub-id><pub-id pub-id-type="pmid">20331614</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollema</surname><given-names>H</given-names></name><name><surname>Hurst</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data</article-title><source>Psychopharmacology</source><volume>235</volume><fpage>2479</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1007/s00213-018-4921-9</pub-id><pub-id pub-id-type="pmid">29980822</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>JE</given-names></name><name><surname>Behm</surname><given-names>FM</given-names></name><name><surname>Westman</surname><given-names>EC</given-names></name><name><surname>Levin</surname><given-names>ED</given-names></name><name><surname>Stein</surname><given-names>RM</given-names></name><name><surname>Ripka</surname><given-names>GV</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone</article-title><source>Clinical Pharmacology and Therapeutics</source><volume>56</volume><fpage>86</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/clpt.1994.105</pub-id><pub-id pub-id-type="pmid">8033499</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouden</surname><given-names>J</given-names></name><name><surname>Ragot</surname><given-names>A</given-names></name><name><surname>Gouault</surname><given-names>S</given-names></name><name><surname>Cahard</surname><given-names>D</given-names></name><name><surname>Plaquevent</surname><given-names>JC</given-names></name><name><surname>Lasne</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Regio- and diastereoselective functionalization of (−)-cytisine: an unusual N–C acyl migration</article-title><source>Tetrahedron</source><volume>13</volume><fpage>1299</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/S0957-4166(02)00271-9</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiefner</surname><given-names>A</given-names></name><name><surname>Breed</surname><given-names>J</given-names></name><name><surname>Bösser</surname><given-names>L</given-names></name><name><surname>Kneip</surname><given-names>S</given-names></name><name><surname>Gade</surname><given-names>J</given-names></name><name><surname>Holtmann</surname><given-names>G</given-names></name><name><surname>Diederichs</surname><given-names>K</given-names></name><name><surname>Welte</surname><given-names>W</given-names></name><name><surname>Bremer</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cation-pi interactions as determinants for binding of the compatible solutes glycine betaine and proline betaine by the periplasmic ligand-binding protein ProX from <italic>Escherichia coli</italic></article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>5588</fpage><lpage>5596</lpage><pub-id pub-id-type="doi">10.1074/jbc.M309771200</pub-id><pub-id pub-id-type="pmid">14612446</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivange</surname><given-names>AV</given-names></name><name><surname>Borden</surname><given-names>PM</given-names></name><name><surname>Muthusamy</surname><given-names>AK</given-names></name><name><surname>Nichols</surname><given-names>AL</given-names></name><name><surname>Bera</surname><given-names>K</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Bishara</surname><given-names>I</given-names></name><name><surname>Jeon</surname><given-names>J</given-names></name><name><surname>Mulcahy</surname><given-names>MJ</given-names></name><name><surname>Cohen</surname><given-names>B</given-names></name><name><surname>O’Riordan</surname><given-names>SL</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Dougherty</surname><given-names>DA</given-names></name><name><surname>Chapman</surname><given-names>ER</given-names></name><name><surname>Marvin</surname><given-names>JS</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors</article-title><source>The Journal of General Physiology</source><volume>151</volume><fpage>738</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1085/jgp.201812201</pub-id><pub-id pub-id-type="pmid">30718376</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DA</given-names></name><name><surname>Allerton</surname><given-names>C</given-names></name><name><surname>Kalgutkar</surname><given-names>AS</given-names></name><name><surname>van de Waterbeemd</surname><given-names>H</given-names></name><name><surname>Walker</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="2012">2012</year><source>Pharmacokinetics and Metabolism in Drug Design</source><publisher-name>Wiley</publisher-name><pub-id pub-id-type="doi">10.1002/9783527645763</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>R</given-names></name><name><surname>Pantoja</surname><given-names>R</given-names></name><name><surname>Moss</surname><given-names>FJ</given-names></name><name><surname>Mackey</surname><given-names>EDW</given-names></name><name><surname>Son</surname><given-names>CD</given-names></name><name><surname>Miwa</surname><given-names>J</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning</article-title><source>The Journal of General Physiology</source><volume>137</volume><fpage>59</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1085/jgp.201010532</pub-id><pub-id pub-id-type="pmid">21187334</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studier</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Protein production by auto-induction in high density shaking cultures</article-title><source>Protein Expression and Purification</source><volume>41</volume><fpage>207</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2005.01.016</pub-id><pub-id pub-id-type="pmid">15915565</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Smoking Cessation in Chronic Obstructive Pulmonary Disease</article-title><source>Seminars in Respiratory and Critical Care Medicine</source><volume>36</volume><fpage>491</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1555610</pub-id><pub-id pub-id-type="pmid">26238637</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsien</surname><given-names>RY</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The green fluorescent protein</article-title><source>Annual Review of Biochemistry</source><volume>67</volume><fpage>509</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.67.1.509</pub-id><pub-id pub-id-type="pmid">9759496</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>JR</given-names></name><name><surname>Castellano</surname><given-names>LM</given-names></name><name><surname>Blendy</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline</article-title><source>Nicotine &amp; Tobacco Research</source><volume>13</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntq206</pub-id><pub-id pub-id-type="pmid">21097981</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname><given-names>EK</given-names></name><name><surname>Keller</surname><given-names>JP</given-names></name><name><surname>Altermatt</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>R</given-names></name><name><surname>Matsui</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Hon</surname><given-names>OJ</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Banala</surname><given-names>S</given-names></name><name><surname>Flanigan</surname><given-names>ME</given-names></name><name><surname>Jaffe</surname><given-names>DA</given-names></name><name><surname>Hartanto</surname><given-names>S</given-names></name><name><surname>Carlen</surname><given-names>J</given-names></name><name><surname>Mizuno</surname><given-names>GO</given-names></name><name><surname>Borden</surname><given-names>PM</given-names></name><name><surname>Shivange</surname><given-names>AV</given-names></name><name><surname>Cameron</surname><given-names>LP</given-names></name><name><surname>Sinning</surname><given-names>S</given-names></name><name><surname>Underhill</surname><given-names>SM</given-names></name><name><surname>Olson</surname><given-names>DE</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name><name><surname>Temple Lang</surname><given-names>D</given-names></name><name><surname>Rudnick</surname><given-names>G</given-names></name><name><surname>Marvin</surname><given-names>JS</given-names></name><name><surname>Lavis</surname><given-names>LD</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Alvarez</surname><given-names>VA</given-names></name><name><surname>Fisher</surname><given-names>AJ</given-names></name><name><surname>Prescher</surname><given-names>JA</given-names></name><name><surname>Kash</surname><given-names>TL</given-names></name><name><surname>Yarov-Yarovoy</surname><given-names>V</given-names></name><name><surname>Gradinaru</surname><given-names>V</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Directed Evolution of a Selective and Sensitive Serotonin Sensor via Machine Learning</article-title><source>Cell</source><volume>183</volume><fpage>1986</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.040</pub-id><pub-id pub-id-type="pmid">33333022</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Ballard</surname><given-names>CC</given-names></name><name><surname>Cowtan</surname><given-names>KD</given-names></name><name><surname>Dodson</surname><given-names>EJ</given-names></name><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>PR</given-names></name><name><surname>Keegan</surname><given-names>RM</given-names></name><name><surname>Krissinel</surname><given-names>EB</given-names></name><name><surname>Leslie</surname><given-names>AGW</given-names></name><name><surname>McCoy</surname><given-names>A</given-names></name><name><surname>McNicholas</surname><given-names>SJ</given-names></name><name><surname>Murshudov</surname><given-names>GN</given-names></name><name><surname>Pannu</surname><given-names>NS</given-names></name><name><surname>Potterton</surname><given-names>EA</given-names></name><name><surname>Powell</surname><given-names>HR</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Vagin</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Overview of the CCP4 suite and current developments</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>67</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1107/S0907444910045749</pub-id><pub-id pub-id-type="pmid">21460441</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiu</surname><given-names>X</given-names></name><name><surname>Puskar</surname><given-names>NL</given-names></name><name><surname>Shanata</surname><given-names>JAP</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Dougherty</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nicotine binding to brain receptors requires a strong cation-pi interaction</article-title><source>Nature</source><volume>458</volume><fpage>534</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1038/nature07768</pub-id><pub-id pub-id-type="pmid">19252481</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec id="s8" sec-type="appendix"><title>iDrugSnFR structural transition</title><p>Because all our iDrugSnFRs derive from the <italic>Thermoanaerobacter</italic> sp. X513 choline/betaine binding protein, we asked whether the design process affected conformational changes between the nonfluorescent and fluorescent states. Principal component analysis showed that component 1 accounted for 75% of the total conformational change, which was associated with a hinge-like motion. Component 2 accounted for 17% of the total conformational change, which was associated with the overall conformational difference between the PBPs of iDrugSnFRs and the other published betaine and choline binding proteins. The liganded and apo biosensor structures partitioned into two groups (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Component 1 accounted for the Venus-flytrap conformational change and was represented best by the structural alignment of varenicline bound to iNicSnFR3adt and the apo iNicSnFR3adt (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). As in other betaine or choline binding protein structures in the Protein Data Bank, the liganded conformations differed little from each other, and the conformational change between liganded and apo states related to the Venus-flytrap mechanism. Component 2 accounted for a small fraction of the conformational differences between the native structures and optimized biosensor. This small difference was also observed when the choline-bound iAChSnFRdtbp and <italic>Bacillus subtilis</italic> structures were aligned (RMSD of 1 Å) (<xref ref-type="bibr" rid="bib18">Fan, 2020</xref>).</p></sec></app><app id="appendix-2"><title>Appendix 2</title><sec id="s9" sec-type="appendix"><title>Further details of kinetic experiments: ‘Methods and results’</title><sec id="s9-1" sec-type="appendix"><title>Millisecond timescale microperfusion with iCytSnFR_PM</title><sec id="s9-1-1" sec-type="appendix"><title>Cell culture</title><p>The iCytSnFR_PM sensor was expressed in HEK293T cells because the high level of protein expression provided by this cell line improved the fluorescent signal/noise ratio. The cells were plated at a density of 1.25 × 10<sup>5</sup> cells per dish on gelatin-coated, glass coverslips attached to the bottom of a 35 mm culture dish and incubated at 37°C. 24 hr after plating, the cells were transfected with iCytSnFR_PM DNA (200 ng per dish) using Lipofectamine 3000 (Thermo Fisher Scientific). The transfection medium was removed after a 24 hr incubation and replaced with fresh growth medium. We incubated the transfected cells for another 24–72 hr to obtain sufficient iCytSnFR_PM membrane protein density for fluorescent imaging.</p></sec><sec id="s9-1-2" sec-type="appendix"><title>Fluorescent microscope</title><p>A blue LED (488 nm wavelength) provided epifluorescent illumination. The bandwidth and peak of the excitation and emission spectra were 460–500 nm and 480 nm (excitation), and 515–550 nm and 535 nm (emission), respectively (Cat. #41001 FITC filter cube). Immediately prior to imaging, we removed the culture dishes from the incubator and rinsed them three times with HBSS warmed to 37°C. After rinsing, we pried the coverslip off the bottom of the dish with a single-edged razor blade and resealed it to the bottom of a plastic perfusion chamber (model RC-25 diamond shape, Warner Instruments) with silicone grease. At this point, the chamber and coverslip were mounted on a motorized microscope stage and perfused continuously with HBSS at 18°C from a gravity-fed, bath perfusion system to keep the cells oxygenated. The fluid level in the chamber was regulated by suction from a syringe needle.</p></sec><sec id="s9-1-3" sec-type="appendix"><title>Drug microperfusion</title><p>The major components of the microperfusion system were (1) a parallel array of three, square glass capillaries (600 µm i.d.) that delivered the ligand to the cells, (2) a stepping motor that translated the capillary array horizontally above the coverslip surface, and (3) a controller that determined the motion and step size of the motor. Both the array and stepping motor were mounted on a motorized micromanipulator (model MP-285, Sutter Instrument Co., Novato, CA) that allowed us to position it in the chamber. Fluid flowed continuously from all three capillaries into the chamber during the experiment, as well as vehicle from a separate input connected to the bath perfusion system. The center capillary in the array contained vehicle plus drug, while the two outer capillaries contained vehicle only. Outflow from the end capillaries kept ligand flow from the center capillary confined to a laminar stream. We applied drugs to the cells in 5–30 s step-like pulses. The array was positioned so that outflow from an end capillary bathed the cells in the field of view with vehicle initially. To apply the ligand to the cells, we stepped the entire array horizontally by 700 µm so that vehicle plus drug from the center capillary bathed the cells. Ligand application was terminated by returning the array to its initial position.</p></sec><sec id="s9-1-4" sec-type="appendix"><title>Data acquisition</title><p>A computer equipped with the Clampex v.9 software and a Digidata 1200 series interface (Molecular Devices, San Jose, CA) controlled both the timing of ligand application and initiated image acquisition. A camera (model ORCA-3G, Hamamatsu, Hamamatsu City, Japan) attached to a microscope port recorded the images. A second computer equipped with the HCImage V3.0 software and a digital camera interface (Hamamatsu) controlled the camera operation, set the parameters of image acquisition, and stored the recorded image sequences. We recorded image sequences of 170–200 frames at rates of 1–8.9 frames/s to visualize the time course of the iCytSnFR_PM response. Event markers in the image file marked the timing of ligand application. We started acquiring images 5–10 s before applying the ligand to establish a baseline fluorescence and continued for 5–180 s after applying drug to record the decay of the response.</p></sec></sec><sec id="s9-2" sec-type="appendix"><title>Millisecond timescale microperfusion with iCytSnFR_PM (results)</title><sec id="s9-2-1" sec-type="appendix"><title>Biphasic decay components of the cytisine response</title><p>One-way ANOVA showed a significant difference between the relative amplitudes of the decay components after the 5, 8, 10, and 15 µM cytisine pulses (ANOVA, p&lt;0.01, df = 3,32). Post-hoc comparisons showed that the relative amplitude of the slow component A<sub>s</sub>/(A<sub>f</sub>+ A<sub>s</sub>) (where A<sub>s</sub> is the amplitude of the slow component and A<sub>f</sub> is the amplitude of the fast) of the 5 μM cytisine decay (24% ± 7%, n = 6 areas [13 cells]) was significantly (Tukey tests, p&lt;0.05) less than the mean A<sub>s</sub>/(A<sub>f</sub> + A<sub>s</sub>) of the three other concentrations (8, 10, 15 µM) (66% ± 1%, n = 30 areas [92 cells]). The A<sub>s</sub>/(A<sub>f</sub> + A<sub>s</sub>)s after pulses of 8, 10, and 15 µM cytisine did not differ significantly (p&gt;0.05).</p></sec><sec id="s9-2-2" sec-type="appendix"><title>Growth phase of the cytisine response</title><p>We visualized the time course of the growth phase of the iCytSnFR_PM response to 1–15 µM cytisine using the Fast-Step microperfusion system (<xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref>). The growth phases of responses to 30 s applications of 1–4 µM cytisine were biphasic and fitted best by the sum of two terms describing an exponential rise to a maximum (<xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1A</xref>). The range of the faster rate constants (kf<sub>on</sub>s) for 1–4 µM cytisine was 0.41–1.22 s<sup>–1</sup> (n = 40 areas [138 cells]), and the range for the slower rate constants was 0.01–0.1 s<sup>–1</sup> (n = 37 areas [128 cells]). The faster component dominated the rising phase of the 1–4 µM cytisine response. The relative amplitude of the faster component A<sub>f</sub>/(A<sub>f</sub> + A<sub>s</sub>) was 77% ± 1%, n = 37 areas (128 cells). It was not affected significantly by cytisine concentration in the 1–4 µM range (ANOVA, df = 3 model, 33 error, p=0.08). The responses to 5–10 s applications of 5–15 µM cytisine reached steady state within a 5 s application. They were fitted adequately by a single negative exponential rise to a maximum (<xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1B</xref>). The single rate constant for the rising phase in individual areas ranged from 0.86 to 2.65 s<sup>–1</sup> (n = 37 areas [133 cells]). We pooled the fast rate constants for the 1–4 µM cytisine responses with the single rate constants for the 5–15 µM responses to obtain an overall [cytisine]-kf<sub>on</sub> relation for the 1–15 µM cytisine concentration range (<xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2A</xref>). Linear least-squares regression showed that the [cytisine]-kf<sub>on</sub> relation over this concentration range was approximately linear (<italic>r</italic> = 0.98, n = 8 concentrations, p&lt;0.05) with a slope and intercept of 1.5 ± 0.1 10<sup>5</sup> (Ms)<sup>–1</sup> and 0.43 ± 0.05 s<sup>–1</sup> (± SE), respectively.</p><p>Nevertheless, the [cytisine]-kf<sub>on</sub> data from the microperfusion experiments deviated from linearity at cytisine concentrations ≥ 8 µM, suggesting that [cytisine]-kf<sub>on</sub> relation for the microperfusion data was more hyperbolic than linear. Using the slower decay rate constant for cytisine (0.146 ± 0.006 s<sup>–1</sup>) as the value for the kf<sub>on</sub> at 0 µM cytisine, a hyperbolic relation fitted the cytisine-kf<sub>on</sub> relation for 0–10 µM cytisine significantly better than a straight line (<xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2B</xref>, F-test, p&lt;0.05).</p><p>In contrast to the faster rate constant of the rising phase kf<sub>on</sub>, the slower rate constant ks<sub>on</sub> decreased significantly as the cytisine concentration increased from 1 to 4 µM (<italic>r</italic> = 0.78, n = 4 concentrations, p&lt;0.05, <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2D</xref>). The slope and intercept of a straight line fit to the [cytisine]-ks<sub>on</sub> data using least-squares regression were –1.5 ± 0.06 × 10<sup>4</sup> M<sup>–1</sup> s<sup>–1</sup> and 0.09 ± 0.2 s<sup>–1</sup> (± SE, n = 4 concentrations), respectively.</p></sec></sec><sec id="s9-3" sec-type="appendix"><title>Comments on a kinetic model</title><p>Our subsecond data with cytisine at iCytSnFR are the most complete, comprising both stopped-flow and HEK293T cell microperfusion. We therefore discuss the cytisine-iCytSnFR kinetics.</p><p>Recent literature on kinetics of PBPs emphasizes a modified induced-fit model with the additional possibility that the apo PBP can also undergo spontaneous activation (termed the ‘closed state’ in the SBP literature; <xref ref-type="bibr" rid="bib13">de Boer et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Gouridis et al., 2015</xref>). Such a scheme, shown in <xref ref-type="fig" rid="app2fig3">Appendix 2—figure 3</xref>, resembles the three-state model we and colleagues developed to account for iSeroSnFR (<xref ref-type="bibr" rid="bib58">Unger et al., 2020</xref>).</p><p>We simulated the scheme using the MATLAB Simbiology toolbox. The following rate constants account for the stopped-flow and millisecond perfusion data within a factor of 3: k<sub>bind2</sub>, 0.5 × 10<sup>6</sup> / M<sup>–1</sup> s<sup>–1</sup>; k<sub>unbind2</sub>, 0.4/ s; k<sub>iso(+)</sub>, 0.001/ s; k<sub>iso(-)</sub>, 0.01/ s; the apo fluorescent state has 0.1 times the brightness of the bound fluorescent state.</p><p>The three-state model predicts the experimental observation (<xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2D</xref>) that the rate constant of the slower component of the kinetics decreases as the ligand concentration increases. For the cytisine-iCytSnFR case reported in this paper, we conclude that the apo, fluorescent state is less bright than the bound state (shown by the different colors of the cpGFP moiety).</p><p>Interestingly, the three-state model fitted the kinetic data best if we assumed that there is a population of higher-sensitivity iDrugSnFRs in HEK293T cells, with an EC<sub>50</sub> at least 10 times less than we observed with the stopped-flow and HeLa cell data. A more complex, ‘square’ four-state model, comprising both ligand binding and protein conformational changes, has been applied to equilibrium measurements of cGaMP (<xref ref-type="bibr" rid="bib3">Barnett et al., 2017</xref>). Full kinetic predictions of the four-state model are available (<xref ref-type="bibr" rid="bib30">Lancet and Pecht, 1976</xref>).</p><p>The fragmentary kinetic data for acetylcholine at iCytSnFR_PM suggest equilibrium and rate constants in the same broad range as for cytisine. However, the kinetic data for varenicline suggest that ligand unbinding dominates the decay phase, with a rate constant &lt;0.01 s<sup>–1</sup>. As a caution, recent data show that mechanisms at PBPs (part of the larger class of substrate binding proteins [SBPs]) can change fundamentally with even a single mutation (<xref ref-type="bibr" rid="bib39">Nguyen et al., 2018</xref>). We therefore wish to avoid generalizing past the single iDrugSnFR we consider here.</p><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Rising phase of the iCytSnFR_PM response to cytisine in HEK293T cells.</title><p>(<bold>A</bold>) Example of the biphasic rising phase of a 1 µM cytisine response in an individual area (black trace, mean of four cells). Cytisine was applied for 30 s. The fast and slow time constants of the rising phase (τf<sub>0n</sub>, τs<sub>0n</sub>) were 2.15 ± 0.05 s and 17 ± 3 s (n = 151 frames, sampling rate of 5 frames/s), respectively. The red line is a fit to the sum of two declining exponentials (R<sup>2</sup> of 0.998). It was significantly better than that to a single negative exponential rise to maximum component and a constant term (F-test, p&lt;0.05). The A<sub>s</sub>/(A<sub>s</sub> + A<sub>f</sub>) was 20%. (<bold>B</bold>) Example of the rising phase of a response to a 5 s application of 5 µM cytisine in an individual area (mean of 10 cells, two replicates). The response appeared to be monophasic with a single time constant (τ<sub>0n</sub>) of 0.76 ± 0.04 s (n = 43 frames, sampling rate of 9.8 frames/s). The red line is a fit to the sum of a negative exponential rise to a maximum, and constant, term (R<sup>2</sup> of 0.98).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-app2-fig1-v2.tif"/></fig><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Concentration dependence of the fast (kf<sub>on</sub>) and slow rising rate constants (ks<sub>on</sub>) of the cytisine response.</title><p>(<bold>A</bold>) The [Cytisine]-kf<sub>on</sub> relation was approximately linear between 1 and 15 µM cytisine. Symbols (filled squares) are the mean kf<sub>on</sub> for the individual cytisine concentrations tested (n = 7–10 areas per concentration, 29–40 cells). The red line is a regression line fit to the data using linear least-squares regression. See text for the values of the slope, intercept, and correlation coefficient. (<bold>B</bold>) The [Cytisine]-kf<sub>on</sub> relation for the kf<sub>on</sub> was more hyperbolic than linear between 0 and 10 µM cytisine. Red line is a fit to the sum of a hyperbolic, and constant, term using nonlinear least-squares regression. See text for fitted parameters. We used the mean slow decay rate constant (ks<sub>off</sub>) of the cytisine response for the kf<sub>on</sub> at 0 µM cytisine (0.146 ± 0.006 s<sup>–1</sup>). (<bold>C</bold>) Concentration–response (CR) relation for the mean steady-state response to cytisine of iCytSnFR_PM sensors expressed in HeLa cells (n = 11 cells, see <xref ref-type="fig" rid="fig7">Figure 7B</xref>). Red line is the fit to the sum of a hyperbolic, and constant, terms using nonlinear least-squares regression. See text for fitted parameters. Symbols (filled squares) are the mean values for the final 10 s of the steady-state cytisine response. (<bold>D</bold>) The [Cytisine]-ks<sub>on</sub> relation for 1–4 µM cytisine. Red line is a regression line fit to the data using linear least-squares regression. See text for the slope, intercept, and correlation coefficient. Symbols (filled squares) are the mean ks<sub>on</sub> for the individual cytisine concentration tested (n = 8–10 areas per concentration, 31–38 cells). Error bars in panels (<bold>A–D</bold>) are ± SEM. Symbols obscure the bars at some concentrations in panels (<bold>A</bold>), (<bold>B</bold>), and (<bold>D</bold>), and all concentrations in panel (<bold>C</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-app2-fig2-v2.tif"/></fig><fig id="app2fig3" position="float"><label>Appendix 2—figure 3.</label><caption><title>A three-state kinetic scheme for iCytSnFR.</title><p>The diagram contains cartoons of the PBP moiety (blue and red), the linkers (black lines), the Glu78 ‘candle snuffer’ attached to Linker 1 (black), and the cpGFP moiety (gray, dark green, or green). We postulate that the intensity-based drug-sensing fluorescent reporter (iDrugSnFR) exists in an apo nonfluorescent state and an apo fluorescent state; these states interconvert with time constants of tens of seconds k(<sub>iso(+)</sub>, k<sub>iso(-)</sub>). Cytisine binds to the apo fluorescent state (k<sub>bind2</sub>), inducing an additional fluorescent state on a briefer time scale. The initial fluorescence increase represents the binding-induced increase, and the slower increase is governed by partial re-equilibration of the two apo states. Upon removal of cytisine after just a few seconds of perfusion (<xref ref-type="fig" rid="fig6">Figure 6</xref>), the fluorescence decay represents the dissociation of cytisine (k<sub>unbind2</sub>). This scheme resembles the model we and colleagues developed to account for iSeroSnFR (<xref ref-type="bibr" rid="bib58">Unger et al., 2020</xref>). For the iDrugSnFRs reported in this paper, we conclude that the apo, fluorescent state is less bright than the bound state (shown by the different colors of the cpGFP moiety).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74648-app2-fig3-v2.tif"/></fig></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74648.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yellen</surname><given-names>Gary</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.10.04.463082" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.04.463082"/></front-stub><body><p>Nichols et al. developed and characterized the first fluorescent sensors for several nicotinic receptor partial agonists relevant to smoking cessation. It is potentially a major advance for the field. They leveraged crystallography to understand the mechanism by which the ligands enhance fluorescence, then characterized top sensors for sensitivity, selectivity, and kinetics, and their utility in plasma membrane and ER sensing in neurons and cell lines. The tools developed by this team will enable investigators to track nicotinic receptor partial agonists in different subcellular compartments with relatively fast time resolution.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74648.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yellen</surname><given-names>Gary</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Hibbs</surname><given-names>Ryan E</given-names></name><role>Reviewer</role><aff><institution>University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Hughes</surname><given-names>Thomas E</given-names></name><role>Reviewer</role><aff><institution>Montana State University</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>McManus</surname><given-names>Owen</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.04.463082">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.10.04.463082v3">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Fluorescence Activation Mechanism and Imaging of Drug Permeation with New Sensors for Smoking-Cessation Ligands&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kenton Swartz as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Ryan E Hibbs (Reviewer #1); Thomas E. Hughes (Reviewer #2); Owen McManus (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Congratulations on an excellent piece of work!</p><p>Essential revisions:</p><p>Please make changes to the text for clarity and answer the individual small questions raised in the reviewers' recommendations below. Also, several reviewers agreed that the impact and interest of the paper for the audience could be broadened by adding a little material to the discussion about how analogous tools may be useful beyond the explicit case of nicotine addiction.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Great read, this is a beautiful piece of work. My only concern is that the paper covers such a broad swath of disciplines that it might be better with additional background? Biosensor people know remarkably little about target engagement issues in drug discover, pharmacologists are only vaguely aware of biosensors, and medicinal chemists are on a different planet. Is there a way to frame the bigger picture beyond nicotine addiction? It's so easy to see how this sort of approach could be used in SAR in different drug discovery campaigns for example.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74648.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Please make changes to the text for clarity and answer the individual small questions raised in the reviewers' recommendations below. Also, several reviewers agreed that the impact and interest of the paper for the audience could be broadened by adding a little material to the discussion about how analogous tools may be useful beyond the explicit case of nicotine addiction.</p></disp-quote><p>The revised Discussion adds the explicit statement:</p><p>“The iDrugSnFR paradigm will be useful beyond the explicit case of nicotine addiction, with application to other exogenous neural drugs.”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Great read, this is a beautiful piece of work. My only concern is that the paper covers such a broad swath of disciplines that it might be better with additional background? Biosensor people know remarkably little about target engagement issues in drug discover, pharmacologists are only vaguely aware of biosensors, and medicinal chemists are on a different planet. Is there a way to frame the bigger picture beyond nicotine addiction? It's so easy to see how this sort of approach could be used in SAR in different drug discovery campaigns for example.</p></disp-quote><p>Amusingly, none of the authors have ever taken a formal course in the disciplines noted: biosensors, drug discovery, pharmacology, medicinal chemistry, or (not mentioned) pharmacokinetics. Lightheartedly, we note that none of us are known to suffer from imposter syndrome.</p><p>More seriously, we have presented 2021 SfN abstracts on related biosensors for opioids, SSRIs, and rapidly acting antidepressants. When those papers are submitted and published, we hope to verify Reviewer 2’s prediction. Meanwhile, the revised Discussion ends with the Editor’s suggested statement:</p><p>“The iDrugSnFR paradigm will be useful beyond the explicit case of nicotine addiction, with application to other exogenous neural drugs.”</p></body></sub-article></article>